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Abstract
HIV-1 strains that use CCR5 predominate after transmission and during the asymptomatic period of disease.
However, in up to half of infected people, variants that use CXCR4 emerge, coincident with accelerated
disease progression. The earliest CXCR4 using strains to appear, called R5X4 viruses, usually retain CCR5 use.
Prototype R5X4 HIV-1 isolates infect macrophages using CCR5 and CXCR4, but CD4+ lymphocyte
infection by these viruses is mediated predominantly by CXCR4. Here, we sought to identify obstacles to
CCR5 use on CD4+ lymphocytes by R5X4 HIV-1. Using a panel of R5X4 Envs we found that, although
CXCR4 was the predominant coreceptor used to infect CD4+ lymphocytes, there was a spectrum of CCR5
use. Greater CCR5 use on lymphocytes correlated with relative resistance to inhibition by CCR5 mAbs and
small molecule antagonists in CCR5+ indicator cells. Increasing CCR5 expression on primary lymphocytes
through cytokine stimulation or lentiviral transduction increased the proportion of entry mediated by CCR5
for all R5X4 isolates except 89.6. Env dependence on CCR5 density was then evaluated using a cell line in
which levels of CD4 and CCR5 could be independently regulated. At non-limiting CD4 levels, strains with
greater lymphocyte CCR5 use were better able to exploit limiting levels of CCR5, whereas those that used
lymphocyte CCR5 poorly were more sensitive to reductions in CCR5 levels. Evaluation of the V3 sequences
of the R5X4 viruses using algorithms that ...
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ABSTRACT 
 
REGULATION OF CCR5 USE ON CD4+ LYMPHOCYTES BY R5X4 HIV-1 
 
Lamorris M. Loftin 
 
Ronald G. Collman 
 
HIV-1 strains that use CCR5 predominate after transmission and during the 
asymptomatic period of disease.  However, in up to half of infected people, variants that 
use CXCR4 emerge, coincident with accelerated disease progression.  The earliest 
CXCR4 using strains to appear, called R5X4 viruses, usually retain CCR5 use.  Prototype 
R5X4 HIV-1 isolates infect macrophages using CCR5 and CXCR4, but CD4+ 
lymphocyte infection by these viruses is mediated predominantly by CXCR4.  Here, we 
sought to identify obstacles to CCR5 use on CD4+ lymphocytes by R5X4 HIV-1.  Using 
a panel of R5X4 Envs we found that, although CXCR4 was the predominant coreceptor 
used to infect CD4+ lymphocytes, there was a spectrum of CCR5 use.  Greater CCR5 use 
on lymphocytes correlated with relative resistance to inhibition by CCR5 mAbs and small 
molecule antagonists in CCR5+ indicator cells.  Increasing CCR5 expression on primary 
lymphocytes through cytokine stimulation or lentiviral transduction increased the 
proportion of entry mediated by CCR5 for all R5X4 isolates except 89.6.  Env 
dependence on CCR5 density was then evaluated using a cell line in which levels of CD4 
and CCR5 could be independently regulated.   At non-limiting CD4 levels, strains with 
greater lymphocyte CCR5 use were better able to exploit limiting levels of CCR5, 
whereas those that used lymphocyte CCR5 poorly were more sensitive to reductions in 
CCR5 levels.   Evaluation of the V3 sequences of the R5X4 viruses using algorithms that 
iv 
predict viral phenotype indicated an association between greater CCR5 use on 
lymphocytes and a predicted non-syncytium inducing phenotype.  Introduction of an 
R306S mutation in the Env V3 domain of 89.6 enhanced its ability to use CCR5 at low 
levels and switched its preference to CCR5 for lymphocyte entry.  Residue R306 in the 
89.6 and C2-16 Envs was also associated with greater dependence on the amino terminus 
of CCR5 for infection.  Thus, lymphocyte CCR5 is used by some R5X4 strains to a 
variable degree, low CCR5 expression coupled with inefficient Env-CCR5 interactions 
are the principal obstacles to lymphocyte CCR5 use by R5X4 HIV-1, and the spectrum of 
lymphocyte CCR5 use by R5X4 isolates is determined by variation in Env-CCR5 
interactions. 
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Chapter I - Introduction 
2 
Origin of the HIV-1 pandemic 
Human Immunodeficiency Virus – type 1 (HIV-1), the causative agent of 
acquired immunodeficiency syndrome (AIDS), is a lentivirus in the family Retroviridae.  
HIV-1 can be grouped into three separate phylogenetic lineages that each entered the 
human population through cross species transmission of Simian Immunodeficiency Virus 
(SIV) from either chimpanzees (Group M and Group N) (Keele et al., 2006) or gorillas 
(Group O) (Van Heuverswyn et al., 2006) in west Africa.  Recently a fourth lineage 
(Group P) (Plantier et al., 2009) was proposed, suggesting that cross-species transmission 
of SIV may still occur.  HIV-1 from groups N and O are found almost exclusively in 
West Africa (Ayouba et al., 2000; Peeters et al., 1997); however, HIV-1 from group M 
spread beyond Africa leading to the global pandemic (Buonaguro, Tornesello, and 
Buonaguro, 2007).  Since the early 20th century, the likely period during which HIV-1 
Group M entered the human population (95), the evolution of this group from a common 
ancestor has resulted in the formation of distinct genetic subgroups, clades A-K, as well 
as numerous circulating recombinant forms of the virus (Buonaguro, Tornesello, and 
Buonaguro, 2007).   The greatest diversity of HIV-1 Group M is found in Sub-Saharan 
Africa, while the pandemic in other parts of the globe is characterized by a high 
prevalence of one or a few specific clades or recombinant forms of the virus (Hemelaar et 
al., 2006).  Over 25 million people have died of infection by HIV-1, and currently 33 
million people globally, including 22 million in Sub-Saharan Africa, are infected by HIV-
1 making it imperative that we understand the pathogenic mechanisms of this virus 
(Merson, 2006; UNAIDS-Epidemic-Update, 2009). 
3 
Overview of HIV-1 pathogenesis 
 HIV-1 is an insidious virus that, in the absence of antiretroviral therapy, slowly 
erodes the capacity of the immune system to respond to pathogens, which ultimately 
causes individuals to succumb to AIDS in an average of 5-7 years (Costagliola et al., 
1989; Ward et al., 1989).  The virus is spread by exposure to blood and other bodily 
fluids containing HIV-1, which occurs through blood product transfusion, IV drug use, 
perinatal exposure and, most commonly, during sexual contact (Curran et al., 1984; 
Harris et al., 1983; Scott et al., 1984).    
 HIV-1 infection and pathogenesis are studied using relevant human lymphoid 
cells and tissues ex vivo or SIV infection in non-human primates, and disease progression 
is monitored by specific measures that are adversely affected by the virus (Fig. 1.1).   
Following mucosal infection by SIV (Stahl-Hennig et al., 1999; Zhang et al., 1999) or 
HIV-1 infection of vaginal explant tissue (Collins et al., 2000; Gupta et al., 2002), virus is 
first found in small foci of infected resting and activated memory CD4+ lymphocytes and 
then later in macrophages and dendritic cells at the initial sites of infection.  Within two 
weeks of SIV infection, virus disseminates from the site of local infection and 
amplification to local draining lymph nodes (Miller et al., 2005; Stahl-Hennig et al., 
1999).   From there, the virus travels through the lymphatic and vascular systems to other 
lymphoid tissue including the gut associated lymphoid tissue (GALT) (Miller et al., 2005; 
Stahl-Hennig et al., 1999).  The majority of activated, memory CD4+ lymphocytes in the 
body are found in the GALT, and HIV-1 infection of CD4+ lymphocytes in this  
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Figure 1.1. Markers of disease progression during HIV-1 infection.   
Acute infection by HIV-1 is characterized by a rapid decline in CD4+ lymphocytes in multiple 
compartments that is coincident with a rapid increase in viral load.  During this stage, the immune system is 
activated to respond to the virus.  CD4+ lymphocytes in peripheral blood, but not in gut mucosal tissue, 
rebound as viral load decreases marking the transition to the chronic phase of infection.  During the chronic 
phase, CD4+ lymphocytes in peripheral blood continue to decline and immune activation increases, which 
is thought to contribute to the immune exhaustion seen later in disease.  Near the onset of AIDS, there is a 
loss of viral control that leads to a spike in viral load, depletion of the peripheral blood CD4+ lymphocytes 
and death.  R5X4 strains typically appear near the onset of AIDS.  Image obtained from Grossman, Z. et al. 
Nature Medicine 2006. 
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compartment leads to rapid and massive cell loss that is sustained throughout disease (Fig 
1.1) (Brenchley et al., 2004; Schieferdecker et al., 1992; Schneider et al., 1994).  HIV-1 
replication in the GALT invokes a robust immune response and induces apoptosis of 
intestinal epithelium that damages the lining of the gut (Li et al., 2008; Sankaran et al., 
2008; Schmitz et al., 2001).  Microbial products are thought to enter peripheral blood as a 
consequence of the breakdown of the intestinal barrier and induce immune activation that 
increases as disease progresses and has been hypothesized to directly contribute to the 
immunodeficiency that occurs at the end of disease (Fig 1.1) (Brenchley et al., 2006).    
Although HIV-1 infection after the acute phase is clinically asymptomatic, covert 
viral replication proceeds for years until the final stage of disease (Embretson et al., 1993; 
Pantaleo et al., 1993).  Humoral and cellular HIV-1-specific immune responses arise 
weeks after transmission; however, in most cases, they fail to adequately control viral 
replication, instead providing selective pressure that contributes to viral evolution (Allen 
et al., 2005; Wei et al., 2003).  As HIV-1 disease progresses, the number of CD4+ 
lymphocytes in blood slowly declines (Polk et al., 1987).   The opportunistic infections 
that characterize AIDS typically begin to occur once CD4+ lymphocyte levels fall below 
a threshold (Eyster et al., 1989), and infected individuals ultimately die from an inability 
to clear virulent as well as opportunistic microorganisms (Fig. 1.1) (Quagliarello, 1982).  
HIV-1 pathogenesis begins at the interface between the virus and cellular 
membranes.  HIV-1 requires a receptor, CD4 (Dalgleish et al., 1984; Klatzmann et al., 
1984), and a seven-transmembrane domain chemokine coreceptor, either CCR5 (Choe et 
al., 1996; Deng et al., 1996) or CXCR4 (Berson et al., 1996; Feng et al., 1996), for 
infection of target cells.  Viruses are typically classified based on the coreceptors they use 
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to infect CD4+ cells lines: R5 viruses use CCR5, X4 viruses use CXCR4, while R5X4 
viruses are able to use either coreceptor (Robertson et al., 2000).  Differences in 
coreceptor use between HIV-1 variants have important implications for transmission and 
pathogenesis.  R5 HIV-1 predominates in the early and asymptomatic stages of infection 
(Schuitemaker et al., 1991); however, in up to 50% of subtype B-infected individuals, 
viruses that use CXCR4 emerge (Spijkerman et al., 1995).  Memory lymphocytes are the 
preferential targets of R5 viruses, but the emergence of CXCR4 use leads to an expansion 
in target cell tropism to include naïve lymphocytes as well (Blaak et al., 2000; Ostrowski 
et al., 1999).  The appearance of these variants and the expanded tropism that results is 
associated with an accelerated decline in the number of CD4+ lymphocytes in peripheral 
blood and rapid progression to AIDS and death (Koot et al., 1993), but presently, it is 
unclear whether the emergence of CXCR4-using viruses is a cause or consequence of 
immune decline.  Interestingly, regardless of virus quasispecies in the donor or the route 
of transmission, nearly all HIV-1 infections are initiated by R5 viruses (van't Wout et al., 
1994; Zhu et al., 1993).  Although there is evidence suggesting mutational barriers and 
selective immune pressure oppose the emergence of CXCR4-using viruses (Harouse et 
al., 2003; Pastore, Ramos, and Mosier, 2004), it is unclear what factors regulate the 
appearance of these variants and why predominately R5 strains transmit.  R5X4 viruses 
are the first CXCR4-using variants to appear (van Rij et al., 2000), and despite CCR5 use 
on indicator cells, these viruses rarely establish infections after transmission (Cornelissen 
et al., 1995; Pasquier et al., 1998).  Consequently, studies focused on R5X4 HIV-1 may 
shed light on these two critical aspects of HIV-1 infection: the emergence of CXCR4 use 
and the bottleneck at transmission that selects for R5 viruses. 
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Figure 1.2. Steps in the gp120 mediated membrane fusion process.   
The HIV-1 Env and the cellular receptor (CD4) and coreceptors (CCR5/CXCR4) are shown on the viral 
and host cell membranes, respectively.  CD4 binding leads to conformational changes in gp120 that result 
in the formation of a coreceptor-binding site.  Coreceptor binding causes additional structural changes in 
gp120 that lead to insertion of the fusion peptide of gp41 into the target cell membrane.  Creation of the 
six-helix bundle in gp41 brings the virus and target cell membrane into close proximity ultimately resulting 
in membrane fusion and viral entry. This image was modified from Nathanson and Overbaugh, Viral 
Pathogenesis and Immunity 2006 
8 
Function and structure of the HIV-1 envelope protein  
 The HIV-1 lipid membrane is studded with the envelope (Env) glycoprotein, 
which is arranged on the surface of the virion as a trimer (Gelderblom et al., 1987).  This 
protein is composed of gp120, the surface subunit, non-covalently attached to the 
transmembrane subunit gp41, which contains the fusion peptide (Earl, Doms, and Moss, 
1990; Freed, Myers, and Risser, 1990).   As outlined in Figure 1.2, HIV-1 entry is a 
multistep process that begins with binding between gp120 and CD4 (Dalgleish et al., 
1984; Klatzmann et al., 1984).  In addition to tethering the virus to target cells, CD4-
gp120 binding also triggers conformational changes in Env that create a coreceptor 
binding site (Sattentau and Moore, 1991).  A number of seven-transmembrane G-protein-
coupled receptors serve as coreceptors for HIV-1 in vitro (Edinger et al., 1998a; Edinger 
et al., 1998b), but only CCR5 and CXCR4 are thought to play a significant role for 
infection in vivo (Scarlatti et al., 1997).  Coreceptor binding is required to complete the 
conformational changes in Env that lead to membrane fusion (Mkrtchyan et al., 2005; 
Oravecz, Pall, and Norcross, 1996).   
 Virus-host membrane fusion is mediated by gp41.  Gp41 has a an N-terminal 
fusion peptide that is inserted into the target cell membrane following receptor binding 
(Freed, Myers, and Risser, 1990; Gallaher, 1987) and two heptad repeats (HR1 and 2) 
that fold back on each other following insertion of the fusion peptide (Chan et al., 1997; 
Weissenhorn et al., 1997).  Formation of this 6-helix bundle brings the HIV-1 and target 
cell membranes into close proximity (Melikyan et al., 2000).  The exact mechanisms that  
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Figure 1.3. Env structure and variability. 
 The 2D amino acid structure of the R3A Env is pictured with the location of the variable loops denoted 
(A).  Predicted N-linked glycosylation sites are indicated by black dots, and the N-terminal leader sequence 
is cleaved where indicated.  The structure of gp120 is shown without the variable loops (B) or CD4-
triggered with the V3 loop (C).  (A) The molecular surface of monomeric gp120 core showing the inner 
domain (left side) and the heavily glycosylated outer domain (right side), which is modeled with complex 
(light blue) or high-mannose (dark blue) sugars.  The location of the variable loops is indicated.  Color 
coding signifies the sequence variability of the indicated residues: red, highly conserved between primate 
lentiviruses, orange, highly conserved between HIV-1 viruses, yellow, variable between HIV-1 viruses, 
green, significant variability between HIV-1 viruses.  (B) CD4-triggered gp120 structure with V3 loop 
extended toward the cell surface. The CD4 structure is superimposed showing the orientation of the gp120 
trimer towards the host cell membrane.  R3A 2D sequence obtained from G. Leslie (U. of Pa.).  Gp120 
images from Wyatt, R. et al. Nature 1998 (B), and Huang, C. et al. Science 2005 (C) 
B C 
A 
V1 
V2 
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join the viral and cellular lipid bilayers are unknown, but following membrane fusion, the 
capsid core is released into the cell.  Upon viral entry, reverse transcription, nuclear  
import, integration of viral cDNA, viral gene expression, mRNA export, protein synthesis 
and virion assembly occur, ultimately leading to the formation of new HIV-1 viruses 
(Greene and Peterlin, 2002). 
The conformational changes that have to occur in gp120 for entry to proceed are 
directly related to the complex structure of the protein.  The surface subunit of Env can 
be divided based on patterns of genetic diversity between isolates into five conserved 
regions and five variable regions, V1-V5, which correspond to disulfide bonded loops 
(Fig. 1.3a) (Starcich et al., 1986).  Additionally, gp120 is heavily glycosylated (Leonard 
et al., 1990).  Structural studies of gp120 monomer without its variable loops reveal a 
core that is divided into an inner and outer domain (Fig. 1.3b) (Chen et al., 2005; Kwong 
et al., 1998).  The more conserved inner domain forms the interacting surface within the 
trimer, while the glycosylated outer domain is exposed (Kwong et al., 1998).  The CD4 
binding site and portions of the coreceptor binding region, including the bridging sheet, 
are non-contiguous on the surface of gp120, and the coreceptor binding domains are also 
partially concealed by variable loops V1/V2 and V3 (Chen et al., 2005).  CD4 binding 
causes conformational changes, primarily within the inner domain, that result in 
formation of the bridging sheet and extension of the V3 loop toward the cell surface, 
ultimately facilitating coreceptor binding (Fig. 1.3c) (Huang et al., 2005; Kwong et al., 
1998). 
   
11 
Molecular determinants of coreceptor use 
 The V3 loop is the most critical determinant of coreceptor use by HIV-1.  The V3 
loop is typically around 35 amino acids long and its structure consists of a base, stem and 
tip (Leonard et al., 1990).  The tip and stem of V3 are thought to interact with the extra 
cellular loops of the coreceptor, while the base interacts with the coreceptor N-terminus 
(Huang et al., 2007; Huang et al., 2005).  Studies have shown that only a few mutations 
within V3 are necessary to alter coreceptor use (de Jong et al., 1992a; Shioda, Levy, and 
Cheng-Mayer, 1992).  The presence of positively charged amino acids at positions 11 and 
24 or 25 within the stem of V3 are associated with the ability to use CXCR4 (Cardozo et 
al., 2007; de Jong et al., 1992a; Fouchier et al., 1992).  Moreover, deletion of three amino 
acids in the stem of V3, ∆9-12, eliminates CXCR4 use by prototype R5X4 viruses, while 
deletions within the base of V3 abolish CCR5 use by these strains (Nolan, Jordan, and 
Hoxie, 2008). Another characteristic frequently associated with CXCR4 use by HIV-1 is 
a high net positive charge within V3 (Fouchier et al., 1992).  Post-translational 
modifications within V3 can also impact viral coreceptor use; the presence of N-linked 
glycosylation in the base of V3 has been shown to determine CCR5 versus CXCR4 use 
for some isolates (Ogert et al., 2001; Pollakis et al., 2001).  
 The bridging sheet and V1/V2 loops are in close proximity to the coreceptor-
binding site, and changes within these regions can also have implications for coreceptor 
use.  Mutations within the bridging sheet can increase sensitivity to CCR5 or CXCR4 
antagonists, indicating that this domain contributes to the efficiency of interaction with 
coreceptor (Reeves et al., 2002).  Mutations within V1/V2 also affect how efficiently Env 
interacts with the coreceptor.  Removing either of two N-linked glycans within the V1/V2 
12 
domain of DH12, an R5X4 virus, decreased CCR5 and CXCR4-mediated infection 
(Ogert et al., 2001).  Furthermore, replacing the V1/V2 of R5 Envs with the 
corresponding domains from Envs that use CXCR4 can permit use of this coreceptor 
(Cho et al., 1998; Pollakis et al., 2001), and the efficiency of CXCR4 use in this context 
is regulated, in part, by glycosylation within V1/V2 (Pollakis et al., 2001).  As critical 
determinants of coreceptor use, the bridging sheet, V1/V2 and V3 also influence target 
cell tropism.  
 
Target cell tropism and viral phenotype 
HIV-1 entry is a critical aspect of viral pathogenesis and a primary determinant of 
which cell types are infected by the virus.  CD4, CCR5 and CXCR4 are expressed on a 
number of immune cells including T helper lymphocytes, monocytes, macrophages and 
dendritic cells (Bleul et al., 1997; Terhorst et al., 1980; Wood, Warner, and Warnke, 
1983; Zaitseva et al., 1997).  CD4+ lymphocytes are the primary targets for HIV-1 
infection and replication in vivo (Massari et al., 1990; Spear et al., 1990), while 
macrophages are though to be a source of viral replication in numerous tissues (Eilbott et 
al., 1989; Jeffrey et al., 1991).  Although HIV-1 infects monocytes and dendritic cells in 
vivo, infection of these cells is infrequent (Cameron et al., 1992; Spear et al., 1990), and 
in the case of monocytes, is more common late in disease (McElrath, Pruett, and Cohn, 
1989).   Maturation-dependent intracellular blocks to HIV-1 replication in dendritic cells 
and monocytes may explain why a low percentage of these cells are infected in vivo 
(Bakri et al., 2001; Sonza et al., 1996).   
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. HIV-1 coreceptor use and target cell tropism.  
Target cell tropism is indicated for the particular HIV-1 virus. L-R5, lymph node derived R5 isolates that 
poorly infect primary macrophages, B-R5, brain derived R5 viruses infect macrophages and lymphocytes; 
P-X4, primary isolate X4 viruses infect all three cell types; LA-X4, lab-adapted X4 viruses infect primary 
lymphocytes, and R5X4 viruses infect both primary cell types.  Illustration modified from Collman and 
Goodenow. Journal of Immunology 2006 
L-R5 B-R5 R5X4 P-X4 LA-X4 
Virus 
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 Early characterization of HIV-1 target cell tropism revealed that some viral 
isolates infected primary CD4+ lymphocytes and lymphocyte cell lines but not 
macrophages.  These isolates were called syncytium-inducing (SI) or T cell (T) tropic 
isolates because of their ability to induce cell-cell fusion, or syncytia, in CD4+ 
lymphocyte cell lines (Fig. 1.4).  SI isolates grew rapidly in vitro and were typically 
recovered at late stages of infection (Asjo et al., 1986; Tersmette et al., 1988).  Another 
class of HIV-1 isolates was found at earlier stages of disease.  These isolates infected 
CD4+ macrophages and primary lymphocytes, replicated slowly, did not infect CD4+ 
transformed cell lines (and thus did not induce syncytia in them) and were therefore 
called non-syncytium-inducing (NSI) or macrophage (M) tropic isolates (Fig. 1.4) (Asjo 
et al., 1986; Tersmette et al., 1988).  Interestingly, M-tropic isolates did not infect T cell 
lines and most T-tropic isolates replicated poorly in macrophages (Schuitemaker et al., 
1991; Schwartz et al., 1989).  Following the identification of CCR5 and CXCR4 as 
coreceptors, it became apparent that differences in target cell tropism for M-tropic and T-
tropic isolates were in large part related to target cell expression of CCR5 or CXCR4, 
respectively, and current classification schemes are now largely based on coreceptor use.  
R5 viruses use CCR5 for infection and X4 use CXCR4, while R5X4 viruses can infect 
cells expressing CCR5 or CXCR4 (Berger et al., 1998).   
 
Coreceptor use and viral tropism 
 The combination of receptor and coreceptors expressed on a cell clearly 
influences HIV-1 tropism.   However, viruses within a strain can vary considerably in the 
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use of CCR5 or CXCR4 when expressed on different cells, which also has an impact on 
cell tropism and pathogenesis.  As mentioned, lab-adapted and primary X4 isolates 
efficiently infect primary lymphocytes using CXCR4 (Gartner et al., 1986; Tersmette et 
al., 1988); however, lab-adapted X4 isolates show a reduced ability to use CXCR4 on 
macrophages when compared to some X4 primary isolates (Fig. 1.4) (Verani et al., 1998; 
Yi et al., 1999).  This difference in tropism results from the inability of lab-adapted X4 
viruses to use the low levels of CXCR4 expressed on primary macrophages (Tokunaga et 
al., 2001), which may be a consequence of prolonged passage on CD4+ cell lines in vitro.  
There are other examples of physiologically relevant variation in receptor use within a 
strain.  R5 Envs cloned from brain typically infect macrophages more effectively than R5 
Envs recovered from peripheral blood and tissue despite similar infection levels on 
lymphocytes (Fig. 1.4) (Peters et al., 2004; Peters et al., 2006).  Furthermore, differences 
in macrophage tropism between brain-derived R5 viruses have important implications for 
viral pathogenesis.  Neurovirulent R5 HIV-1 from patients with dementia show an even 
greater capacity to infect macrophages than R5 viruses isolated from brains of patients 
with no signs of neurological impairment (Gorry et al., 2002a).  In both cases, enhanced 
macrophage tropism is mediated either by increased CCR5 affinity (Gorry et al., 2002a) 
or by an ability to efficiently utilize low levels of CD4 or CCR5 for infection (Dunfee et 
al., 2006; Gorry et al., 2002a; Peters et al., 2004).    
 The relationship between coreceptor use and target cell tropism is quite complex 
and is unique for each HIV-1 strain.  It is critical that we fully understand the variation in 
coreceptor use by HIV-1 strains and its affects on target cell tropism because of the 
important role these two factors play in HIV-1 transmission and pathogenesis. 
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Emergence of CXCR4 use: an overview 
Longitudinal studies of HIV-1 reveal that R5 isolates predominate during the 
early and the asymptomatic period of disease (Schuitemaker et al., 1991).  However, 
nearly half of subtype-B infected individuals develop CXCR4-using variants (Spijkerman 
et al., 1995) (as do a number of people infected with other subtypes, except for subtype C 
which acquires CXCR4 use infrequently (Abebe et al., 1999; Tscherning et al., 1998)) .  
The emergence of CXCR4-using viruses is associated with accelerated loss of CD4+ 
lymphocytes and rapid progression to AIDS (Koot et al., 1993).   However, it remains 
unclear whether viruses capable of using CXCR4 arise in response to a weakened 
immune system, whether these viruses cause the accelerated immune decline associated 
with their emergence or if both phenomena occur.  Unraveling this complex relationship 
as well as identifying the factors that regulate the emergence of CXCR4 use will help 
more clearly define the role of viral evolution in disease progression and may have 
implications for other stages of infection. 
 
Emergence of CXCR4 use: intrinsic mutational barriers 
In some cases, as little as two amino acid changes are sufficient to convert a virus 
from R5 to R5X4 (Kiselyeva et al., 2007; Pastore, Ramos, and Mosier, 2004), yet 
variants that use CXCR4 arise in only half of infected patients, suggesting barriers to 
their emergence.  Studies of viral evolution in vitro and in vivo reveal complex 
mutational pathways from CCR5 to CXCR4 use that are beset with obstacles.  In one 
study, nearly all R5X4 viruses derived in vitro replicated more poorly and were more 
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sensitive to CCR5 antagonists than the parental R5 viruses (Pastore, Ramos, and Mosier, 
2004).  Additionally, when the mutations that accrued were individually reinserted into 
the parental R5 virus, the mutations within the V3 loop that switched coreceptor use 
resulted in non-functional viruses.  Mutations within the V3 loop only resulted in 
functional Envs with CXCR4 use when they were preceded by mutations in V1/V2 
(Pastore et al., 2006).  In a patient followed for years before and after coreceptor switch, 
there was a reduction in the efficiency of CCR5 use by R5 viruses and rapid divergence, 
not only within V3, but in the V4/V5 loops as well, prior to the emergence of R5X4 
viruses (Coetzer et al., 2008).  These studies suggest that mutations within other domains 
of Env are required prior to or concurrent with the changes in V3 for CXCR4 use to 
emerge, and this multistep process is a barrier to the acquisition of CXCR4 because it 
negatively impacts CCR5-mediated entry and frequently results in non-functional Envs.   
 
Emergence of CXCR4 use: immune suppression of CXCR4-using viruses 
The difficult mutational pathways that lead to CXCR4 use are an intrinsic 
obstacle to coreceptor switching.  However, the immune response to the virus also 
appears to impede this process.  It has been reported that, following the acquisition of 
CXCR4 use, X4 viruses are more sensitive to neutralizing antibodies than coexisting R5 
viruses (Bunnik et al., 2007).  Support for the notion that CXCR4-using viruses are 
preferentially targeted by the host immune response also comes from acute infection.  A 
few anecdotal cases have suggested that after a brief period of replication, CXCR4-using 
HIV-1 variants can be selectively suppressed following coinfection with viruses that use 
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CCR5 (Cornelissen et al., 1995; Veenstra et al., 1995).  A similar observation was made 
in a macaque coinfection study in which the R5 SHIV remained detectable while the X4 
SHIV became undetectable in some animals coincident with the establishment of a 
SHIV-specific immune response.  Depletion of CD8+ lymphocytes in these animals led 
to the reemergence of the X4 SHIV to levels similar to those of the R5 SHIV, and the X4 
SHIV returned to undetectable levels after the CD8+ lymphocytes rebounded (Harouse et 
al., 2003).  These findings suggest the immune response to HIV-1 suppresses X4 variants 
and that the loss of immune control may contribute to the emergence of CXCR4-using 
viruses.  On the other hand, recent data suggests that most people who sexually acquire 
HIV become infected with a single variant, which is usually R5 (although whether X4 
viruses are suppressed by local innate immune responses during mucosal replication is 
unknown) (Keele et al., 2008a). 
While it remains unresolved, there is a substantial body of work suggesting that 
immune decline precedes the emergence of CXCR4 use because the antiviral immune 
response is more effective against these strains.  The transmission and establishment of 
R5X4 viruses have been associated with poor humoral and cytotoxic cellular immune 
responses (Dalmau et al., 2009), although, it is not clear whether pronounced immune 
dysfunction enabled R5X4 infection or whether infection by R5X4 strains precipitated 
the immune destruction.  In this regard, macaque models of coreceptor switch may be 
informative.  The emergence of CXCR4-using SHIVs in macaques infected with CCR5-
using viruses occurred in animals with high viral load, poor cellular immune response 
and undetectable antibody response to the virus (Ho et al., 2007; Ren et al., 2010), 
suggesting that immune decline precedes the appearance of variants that use CXCR4.   
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Emergence of CXCR4 use: CCR5+ target cell depletion  
Another factor proposed to drive the acquisition of CXCR4 use is target cell 
depletion.  R5 HIV-1 preferentially infects memory lymphocytes, while naïve 
lymphocytes, which lack CCR5 expression, are rarely targeted by these viruses (Blaak et 
al., 2000; Rabin et al., 1999).  Acquisition of CXCR4 use results in a marked increase in 
infection of naïve lymphocytes (Blaak et al., 2000; Ostrowski et al., 1999).  Preferential 
infection of CCR5+ memory lymphocytes coupled with expanded targeting of naïve 
lymphocytes following acquisition of CXCR4 use has lead to the hypothesis that 
depletion of CCR5+ targets cells creates pressure that selects for viruses with CXCR4 
use.  CCR5+ target cell depletion and lack of immune control are not mutually exclusive; 
these factors may act in concert to promote the acquisition of CXCR4 use.  One 
interpretation of the results from the macaque model of coreceptor switch mentioned 
above is that poor immune control results in high levels of viral replication, increasing 
the chances of the emergence of mutant viruses that use CXCR4 while creating an 
environment that would allow greater depletion of CCR5+ target cells.   
Conversely, an expansion in target cell tropism coupled with more rapid, 
cytopathic infection by R5X4 and X4 viruses suggests a viral component to the decline in 
cell numbers seen when these viruses are present.  Infection by viruses that use CCR5 or 
CXCR4 are equally cytopathic for their target cells in vitro (Kwa et al., 2001) and in ex 
vivo lymphoid tissue (Grivel and Margolis, 1999).  However, in blood, central and 
effector memory as well as naïve CD4+ lymphocytes express CXCR4, resulting in much 
greater lymphocyte depletion following infection with X4 and R5X4 viruses (Grivel and 
Margolis, 1999; Kwa et al., 2001).  On the other hand, in some CD4+ lymphocytes 
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subsets, such as resting memory cells, CXCR4-using viruses are more cytopathic (Zhou 
et al., 2008), and these variants induce substantially more apoptosis in uninfected 
bystander cells in lymphoid tissue compared to R5 viruses (Jekle et al., 2003).  Animal 
models also indicate that infection with X4 SHIV is more pathogenic than R5 SHIV 
infection (Harouse et al., 1999; Nishimura et al., 2004), resulting in rapid depletion of 
peripheral CD4+ lymphocytes, including naïve cells (Nishimura et al., 2005).  Greater 
infection of naïve lymphocytes likely impairs lymphocyte differentiation and exacerbates 
immune decline.  Although rare, in the instances in which CXCR4-using HIV-1 is 
transmitted and establishes infection, CD4+ lymphocyte numbers decline rapidly and 
progression to AIDS is much faster than the time frame following R5 infection (Yu et al., 
1998).   
 
HIV-1 coreceptor use and transmission  
Heterosexual intercourse is the most common route of HIV-1 transmission, but it 
is nonetheless a very inefficient process.  The probability of HIV-1 transmission from an 
infected individual is infrequent, ranging from 0.04-0.38% per sex act (Boily et al., 
2009).   However, HIV-1 transmission through other routes occurs at higher rates; the 
mother-to-child transmission rate, pre- and intrapartum combined, is approximately 20% 
(Kourtis et al., 2006).  Efforts to understand HIV-1 transmission in different settings have 
revealed a bottleneck at transmission that is associated with genotypic and phenotypic 
selection of newly transmitted HIV-1 variants. 
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Figure 1.5. Selective transmission of R5 HIV-1 from donor to recipient.   
Regardless of the composition of the viral quasispecies in the donor, only R5 viruses are transmitted to the recipient.  It is unclear 
what factors impede the transmission of CXCR4 using viruses, or what selectively promotes the transmission of R5 strains.  R5 target 
cell tropism and X4 immune suppression are two possible barriers to transmission of X4 strains, but there are likely others.  It is clear 
that certain features are common in viruses from the recipient, such as the requirement for CCR5 use, which suggests selection 
targeted at the viral Env. 
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  HIV-1 transmission is associated with a loss in genetic diversity from the donor to 
the recipient that suggests a selective barrier to transmission.  HIV-1 infection is 
generally associated with high levels of genetic diversity (Hahn et al., 1986; Saag et al., 
1988).  However, after transmission, viral diversity in the recipient is much lower than in 
the donor, and this reduced diversity is most evident in the env gene (Verhofstede et al., 
2003; Wolinsky et al., 1992; Zhu et al., 1993).   In fact, in the majority of new sexually 
transmitted HIV-1 infections the env is completely homogeneous (Abrahams et al., 2009; 
Keele et al., 2008a).  Furthermore, recent studies using PCR amplification and 
phylogenetic reconstruction of the successfully transmitted virus indicate a single viral 
variant is usually responsible for seeding infection in the recipient (~80%) with two or 
more variants responsible for the rest (Abrahams et al., 2009; Keele et al., 2008a).   
A number of classic studies suggested that genetic homogenization in the 
recipient was associated with selection at mucosal transmission that favored M-
tropic/NSI isolates with specific exclusion of T-tropic/SI variants.  In these studies, 
viruses from the acute phase of infection were highly M-tropic where as T-tropic variants 
did not arise until later stages of disease (Schuitemaker et al., 1992; van't Wout et al., 
1994; Zhu et al., 1993).  The preponderance of M-tropic variants in a recipient during the 
earliest periods following transmission was seen even when the donor harbored T-tropic 
variants (van't Wout et al., 1994; Zhu et al., 1993), and a few anecdotal studies indicated 
that SI variants could be selectively suppressed following transmission (Cornelissen et 
al., 1995; Pratt et al., 1995).  These early studies concluded that the ability to replicate in 
macrophages is essential for establishing infection in recipients and implied that 
macrophages are likely a major source of virus replication during acute infection.  
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However, more recent in vitro and in vivo studies strongly suggest CD4+ lymphocytes 
are the first cells infected after mucosal transmission (Gupta et al., 2002; Zhang et al., 
1999), variants from periods shortly after transmission do not have enhanced macrophage 
tropism (Isaacman-Beck et al., 2009), and the single, founder virus responsible for 
establishing infection after transmission actually replicates significantly better in CD4+ 
lymphocytes than macrophages (Salazar-Gonzalez et al., 2009).  
 It remains unclear whether target cell tropism is a factor in the bottleneck between 
donor and recipient, but it is apparent that selection for R5 variants and exclusion of 
CXCR4-using viruses occurs during HIV-1 transmission in association with 
characteristic changes in Env.  The V3 domain in Env is a major determinant of target 
cell tropism, and initial characterization of V3 within Envs from acute infection 
suggested selection at transmission that leads to a homogeneous population (Hwang et 
al., 1991; McNearney et al., 1992; Zhang et al., 1993).  The discovery of CCR5 as the 
receptor for M-tropic viruses and the finding that V3 is the principal determinant of 
coreceptor use provided a genotypic basis for the phenotypic selection observed at 
transmission (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 
1996).  Furthermore, the identification of individuals that are protected from HIV-1 
infection due to a 32 base pair deletion in the CCR5 gene, which prevents its expression 
on the cell surface, confirms CCR5 use is required for transmission (Liu et al., 1996; 
Samson et al., 1996).  The requirement for CCR5 at transmission also suggests that V3, 
the major determinant of coreceptor use, is either a direct or an indirect target of selection 
during transmission.  Additionally selection at transmission may also affect other regions 
of Env.  Envs recovered from the earliest time point after transmission of subtype A or C 
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HIV-1 have shorter V1/V2 or V1-V4 length, respectively, and reduced N-linked 
glycosylation (Chohan et al., 2005; Derdeyn et al., 2004) when compared to matched 
donors.  For subtype C, these changes are associated with greater sensitivity to 
neutralization by donor antibody (Derdeyn et al., 2004).  However, these differences in 
Env appear to be subtype-dependent, since there are no changes in either Env length or 
the number of N-linked glycosylation sites following transmission of subtype B viruses 
(Chohan et al., 2005).   
 Selection for CCR5 use clearly occurs during transmission and is required for 
HIV-1 to establish infection in a recipient.  Preferential immune suppression of CXCR4-
using viruses may be one mechanism that accounts for this selection, although it remains 
unclear whether this is the principal means of exclusion or whether CXCR4-using strains 
are not transmitted for other reasons such as the inability to use CCR5 on a particular cell 
type.   
 
Transmission, CCR5 use and tropism by R5X4 HIV-1  
 It is unclear why particular viral strains are the target of selection during 
transmission, which makes the study of R5X4 viruses intriguing and potentially 
informative.  These viruses can infect indicator cells expressing either coreceptor, yet a 
dependence on CCR5 or CXCR4 for infection is associated with drastically different 
outcomes following HIV-1 transmission.  R5 strains predominate following viral 
transmission whereas R5X4 viruses are typically not found during the early or 
asymptomatic period of infection (van't Wout et al., 1994).  If variants that use CXCR4 
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are selected against, R5X4 viruses may be subject to the same repressive forces that are 
thought to oppose transmission of X4 viruses.  Alternatively, if there is positive selection 
for CCR5 use, successful transmission of R5X4 viruses may not occur because these 
viruses uses CCR5 in a different manner than R5 viruses.    
Numerous studies suggest that CCR5 use by R5X4 viruses differs from that of R5 
viruses.  CCR5 is a seven transmembrane protein with an N-terminus (NT) and three 
extracellular loops (ECLs).  The NT of CCR5 is modified by tyrosine sulfation, and 
removal of sulfation within this domain by mutating tyrosine residues reduces infection 
by R5X4 viruses more substantially than infection by R5 viruses (Farzan et al., 1999; 
Rabut et al., 1998).  Additionally, deleting amino acids from the NT of CCR5 has a larger 
impact on infection by R5X4 compared to R5 viruses (Rucker et al., 1996; Yi et al., 
2003b).  The ECLs of CCR5 are also critical domains for coreceptor function. Mutations 
within the ECLs cause a greater decrease in CCR5-mediated infection by R5X4 versus 
R5 viruses (Doranz et al., 1997; Genoud et al., 1999; Yi et al., 2003b).  Inhibitors that 
target this region within CCR5 also have differing effects on R5X4 and R5 viruses.  
Antibodies with epitopes within the ECLs along with small molecule antagonists that 
disrupt this domain typically inhibit R5X4 infection more than infection by R5 viruses 
(Olson et al., 1999; Yi, Shaheen, and Collman, 2005).  This suggests that, compared to 
R5 viruses, R5X4 viruses have less efficient interactions with CCR5.  However, neither 
differences in the efficiency of Env-CCR5 interactions between R5X4 strains nor their 
ramifications for coreceptor use on primary cells have been addressed.  
Coreceptor use by HIV-1 is typically determined on cell lines that express CD4 
and CCR5 or CXCR4 (Björndal et al., 1997; Deng et al., 1997).  While these cell lines 
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are invaluable tools for studying certain aspects of HIV-1 entry and infection, coreceptors 
used on these cell lines may not accurately reflect coreceptor use on primary cells 
(Collman, 1992; Tokunaga et al., 2001).  Previous efforts by our lab to define the 
coreceptors used by a small number of prototype R5X4 HIV-1 on primary cells revealed 
these viruses can infect CD4+ macrophages using either CCR5 or CXCR4; however, in 
CD4+ lymphocytes, CXCR4 was the predominate coreceptor used by R5X4 HIV-1 while 
CCR5-mediated entry made only a marginal contribution to infection.  In the same study, 
R5 viruses readily infected CD4+ lymphocytes suggesting CCR5 use by R5X4 viruses is 
severely impaired on these cells (Yi, Shaheen, and Collman, 2005).  It is unclear how 
widespread the impairment to lymphocyte CCR5 use is for R5X4 viruses, and what 
factors regulate coreceptor use on primary lymphocytes.  Given the selection for CCR5 
use during transmission and the fact that CD4+ lymphocytes are likely the earliest cells 
infected in an HIV-1 recipient, understanding the factors that regulate CCR5 use on 
lymphocytes by R5X4 viruses may help elucidate why these viruses fail to establish 
infections following transmission. 
 
Goals of this thesis 
The goal of this thesis is to better understand the patterns of coreceptor use by 
R5X4 HIV-1 and to identify the factors that regulate CCR5 use on CD4+ lymphocytes by 
this virus strain.  In chapter 3, I determine the extent of CCR5 use on lymphocytes by a 
panel of R5X4 HIV-1 viruses and examine the role of CCR5 expression on CCR5-
mediated infection of CD4+ lymphocytes by these viruses.  My findings reveal a limited 
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spectrum of lymphocyte CCR5 use by the R5X4 viruses in this panel that is determined, 
in part, by low CCR5 expression.  Increasing CCR5 levels on CD4+ lymphocytes 
substantially increased CCR5-mediated entry by all but one virus, 89.6.  In chapter 4, I 
determine the efficiency of the Env-CCR5 interaction based on sensitivity to CCR5 
antagonist, CCR5 antibody blocking and infection of a cell line that expresses inducer-
controlled levels of CD4 and CCR5.  I observed a significant correlation between greater 
lymphocyte CCR5 use and both resistance to CCR5 blocking and reduced sensitivity to 
changes in CCR5 expression. My results suggest viruses with greater lymphocyte CCR5 
use have more efficient interactions with CCR5, which indicates this interaction is the 
main determinant of CCR5 use on these cells.  In chapter 5, I address the impact of 
mutations within V3 on the efficiency of Env interaction with CCR5 and coreceptor use 
by R5X4 HIV-1.  My results show mutating an arginine at position 11 within the V3 of 
89.6 to a serine increased the efficiency of interaction with CCR5 and changed coreceptor 
use on CD4+ lymphocytes from preferential CXCR4 use to predominant CCR5-mediated 
entry.  Mutating this position resulted in 89.6 and C2-16 variants with altered use of the 
CCR5 N-terminus.  This indicates that V3, and position 306 in particular, is a principal 
determinant of Env-CCR5 interactions and CCR5 use for some, but not all, R5X4 
viruses.  Thus, low CCR5 expression is a major obstacle to CCR5 use on lymphocytes by 
R5X4 viruses, and the limited lymphocyte CCR5 use by R5X4 viruses is regulated by the 
efficiency of the Env-CCR5 interaction.  For most R5X4 viruses, the interaction is 
inefficient resulting in poor lymphocyte CCR5 use; however, mutations that increase the 
efficiency of this interaction can enhance CCR5-mediated infection of CD4+ 
lymphocytes. 
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Primary cells and cell lines 
CD4+ lymphocytes were isolated by negative selection from whole blood (Stem 
Cell Technologies, Vancouver, BC, Canada).  Purified lymphocytes were maintained at 
106 cells/ml in RPMI (Invitrogen, Carlsbad, CA) with 10% FBS (Thermo Scientific, 
Waltham, MA) and stimulated for 3 days with 5 µg/ml of phytohemagglutinin (PHA; MP 
Biomedical, Solon, OH) or in 24 well plates coated with 5 µg/ml of anti-CD3 (OKT3; a 
gift of M. Betts, U. of Pa.) and anti-CD28 (clone 28.2; Beckman Coulter, Fullerton, CA) 
antibodies.  Cells were then either infected and maintained thereafter in IL-2, or cultured 
for 10 days in IL-2 (300 U/ml; Proleukin, Novartis, Basel, Switzerland) to upregulate 
CCR5 prior to infection.  293 Affinofile cells that express CCR5 and CD4 under 
independent regulation were maintained in DMEM (Thermo Scientific) with 10%FBS, 
blasticidin, G418, hygromycin and zeocin (Invitrogen) (Johnston et al., 2009; Lassen et 
al., 2009).  293, U87/CD4, U87/CD4/CXCR4 and U87/CD4/CCR5 cells were obtained 
from the NIH AIDS Research and Reference Reagent Program (Björndal et al., 1997; 
Graham et al., 1977).  293 cells were maintained in DMEM with 10% FBS, and the U87 
cell lines were maintained in selective media containing 1 µg/ml of puromycin (MP 
Biomedical, Solon, OH) or 300 µg/ml of G418 (Invitrogen, Carlsbad, CA) for selection 
of CD4 or CCR5 and CXCR4 respectively. 
 
HIV-1 Env, CD4 and coreceptor expression vectors 
  HIV-1 R5X4 prototypes 89.6, DH12, and primary isolate NR Env clones were 
derived from patients with advanced disease and have been previously described 
30 
(Collman et al., 1992; Ray et al., 2007; Shibata et al., 1995).  Env clone R3A was derived 
from an unusual acute seroconverter found to harbor R5X4 variants during acute 
infection, and it has been described previously (Meissner et al., 2004; Yu et al., 1998).  
R5X4 variants C2 and DR were obtained from two HIV-infected CCR5-null individuals 
homozygous for the ∆32 allele (Gray et al., 2006).  The X4 isolate Tybe (from CSF) and 
R5 strains JRFL (from brain) and Bal (from lung) have also been described previously 
(Gartner et al., 1986; Koyanagi et al., 1987; Yi et al., 2003a).  Prototype 89.6, R3A, JRFL 
and Tybe Envs along with NR Envs were subcloned into the expression vector pCAGGS 
(Niwa, Yamamura, and Miyazaki, 1991) using standard methods.  The expression vectors 
used to subclone the remaining vectors have been previously described (Helseth et al., 
1990; Kim et al., 2001).  89.6 and C2-16 envelope clones with mutations at position 11 
within the V3 loop were generated using a Quick Change XL mutagenesis kit 
(Stratagene, La Jolla, CA).  NR Env clones were a gift from R. Doms (U. of Pa.), R3A 
was obtained from J. Hoxie (U. of Pa.) and kindly provided by L. Su (UNC-Chapel Hill), 
and JRFL, DH12 and Bal Env clones were generously provided by M. Cho (Case 
Western Reserve).  
 CCR5 N-terminal deletion (Δ2-5, Δ2-9, and Δ2-13) mutant coreceptors were 
kindly provided by R. Doms and have been previously described (Blanpain et al., 1999). 
CCR5 N-terminal tyrosine (Y3A, Y10A, Y14A and Y15A) mutant coreceptors were 
kindly provided by G. Leslie and J. Hoxie (U. of Pa.), and were created using the Quick 
Change XL mutagenesis kit and sequence specific primers containing the appropriate 
nucleotide substitutions. Coreceptors with these mutations have been described elsewhere 
(Dragic et al., 2000; Genoud et al., 1999; Lee et al., 1999a; Siciliano et al., 1999) 
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Pseudotype virus production  
HIV-1 Env luciferase pseudotype viruses were generated by cotransfecting a 
plasmid that expressed HIV-1 structural proteins (pCMVΔP1ΔenvpA), a plasmid that 
expressed the packaged luciferase reporter (pHIV-1 luc), and an HIV-1 or VSV-G Env 
plasmid.  Plasmids were cotransfected into 293 cells using Fugene transfection reagent 
(Roche, Palo Alto, CA) at ratios of 1:3:1 as previously described (Sterjovski et al., 2007; 
Yang et al., 2004).  GFP reporter viruses were created by cotransfection of structural 
gene plasmid pHp1, GFP reporter plasmid pHRET-GFP, the tat expression plasmid 
pCep4-tat, and a plasmid expressing an HIV-1 or VSV-G Env.  Plasmids were 
cotransfected into 293 cells at a ratio of 10:10:1:10 as previously described (Chang et al., 
1999).  The CCR5 lentiviral expression vector pNL-CCR5 was created from pNL-CD4 
by digestion with NotI and XhoI to remove CD4, and the CCR5 gene was amplified 
(sense primer 5’-TAG TGC TGT TAA CTT GCT CAA TGC-3’ and antisense 5’-GAT 
CAA GGA TAT CTT GTC TTC-3’) and subcloned into the NotI and XhoI sites.  CCR5 
transduction vectors were produced by cotransfecting pRev, pNL-CCR5 and pVSV-G 
into 293 cells at a ratio of 1:2:1.   
HIV-1 Env pseudotype viruses and lentiviral expression vectors were harvested 
48 hours after transfection, clarified by centrifugation at 250xg, then stored in 5% sucrose 
at -80°C until use. Plasmids pCMVΔP1ΔenvpA (Parolin et al., 1996) and pHIV-1-luc 
(Yang et al., 2004) were generously provided by J. Sodroski (Harvard University), and 
pNL-CD4 (Tokunaga et al., 2001) was kindly provided by B. Cullen (Duke University).  
Plasmid pHRET-GFP (Lin et al., 2002) was provided by P. Corbeau (Hôpital Saint Eloi) 
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and pHp1 and pCep4-tat (Chang et al., 1999) were a gift from J. Zucali (University of 
Florida) obtained through the NIH AIDS Research and Reference Reagent Program.   
  
CCR5 over-expression in CD4+ lymphocytes 
PHA-stimulated CD4+ lymphocytes were pelleted (250xg at 25°C for 5 minutes) 
and resuspended at 2x106 cells per ml in media containing 8 µg/ml of Polybrene.  Cells 
were then transduced using 200 µl of CCR5 expression vector pNL-CCR5, spin 
inoculated for 2 hours as described (O'Doherty, Swiggard, and Malim, 2000), then 
incubated in the presence of 10 U/ml of IL-2 at 37°C and 5% CO2 for 72 hours.  After 
this period, coreceptor expression was analyzed by FACS and cells were used for 
infection. 
 
Infection of cell lines and CD4+ lymphocytes 
U87 cells were plated in 96 well plates at 1.5x104 cells per well one day prior to 
infection, infected by spin inoculation at 1200xg for 2 hours with HIV-1 pseudotype 
viruses (5 ng of p24 antigen per virus), and cultured at 37°C and 5% CO2 for three days.  
For blocking studies, U87/CD4/CCR5 cells were pretreated for 1 hour and then infected 
in the presence of 10 µg/ml of CCR5 mAb or serial dilutions of the CCR5 small molecule 
antagonists. Luciferase activity was measured by lysing cells in PBS containing 0.1% 
Triton X-100, combining cell lysate 1:1 with luciferase assay substrate (Luciferase Assay 
System; Promega, Madison, WI) and measuring luciferase relative light units (RLUs) 
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using a Dynex technologies microtiter plate luminometer.  CCR5 monoclonal antibodies 
2D7, 45531 and CTC8 were obtained from the NIH AIDS Research and Reference 
Reagent Program, and mAb MC-1 (Blanpain et al., 2002) was a gift from M. Mack 
(University of Munich).  The CCR5 blocker M657 (Finke, 2000) was a gift from M. 
Miller (Merck, W. Point, PA), and Maraviroc (Dorr et al., 2005) (Pfizer Inc., New York 
City, NY) was obtained through the NIH AIDS Research and Reference Reagent 
Program. 
CCR5 wt and mutant coreceptor use was evaluated in 293 cells by plating cells in 
6 well plates at 8x105 cells/well 24 hours before transfection.  Cells were transfected 
using Fugene transfection reagent with 1µg of a plasmid that expressed CD4 either alone 
or in combination with 1µg of plasmid expressing wt or mutant CCR5.  Cells were 
washed twice with media the day after transfection, and 48 hours post transfection, cells 
were removed with 2mM EDTA in PBS and replated either at 1.5x104 cells/well in 96 
well plates for infection or at 8x105 cells/well in a 6 well plate for FACS. The following 
day, cells were analyzed for CD4 and coreceptor expression as described below or 
incubated with AMD3100 (1 µg/ml; Sigma-Aldrich, St. Louis, MO) for one hour then 
infected with 5 ng of HIV pseudotypes by spinoculation as previously mentioned.  
Infection levels were determined after 72 hours by lysing cells and measuring luciferase 
activity in the cell lysates as detailed for U87 cells.  
For infection of primary cells, PHA or CD3/CD28-stimulated CD4+ lymphocytes 
were added to 96 well plates at 2x105 cells per well.  Cells were pretreated for 1 hour 
with saturating concentrations of CCR5 antagonists M657 (5 µg/ml) or Maraviroc (2 
µM), the CXCR4 antagonist AMD3100 (5 µg/ml) or a combination of CCR5 and 
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CXCR4 blockers.  Following pretreatment, CD4+ lymphocytes were infected in the 
presence of the inhibitors using an equal volume or 10 ng of p24 antigen per virus for 
PHA or CD3/CD28-stimulated cells, respectively.  CD4+ lymphocytes were infected by 
spin inoculation at 1200xg for 2 hours, and then cultured at 37°C and 5% CO2 in the 
presence of IL-2 for 3 days.  Infection was measured by luciferase activity in the cell 
lysate as previously described, or by FACS analysis of GFP expression.   
Infection of 293 Affinofiles has been described in detail previously (Johnston et 
al., 2009; Lassen et al., 2009).  To briefly summarize, cells were plated at 1.5x104 cells 
per well in 96 well plates in media containing 2% dialyzed FBS.  Cell were allowed to 
adhere for two days, then media was removed and replaced with media containing a fixed 
concentration of the CD4-inducing reagent Minocycline (0.625 ng/ml) and varying 
concentrations of the CCR5 inducer Ponasterone (0-2 µM).  After an overnight 
incubation, cells were pre-treated for at least 1 hour with 1 µg/ml of AMD3100 to block 
CXCR4 in media containing 10% dialyzed FBS, then infected by spin inoculation using 1 
ng of p24 antigen per luciferase pseudotype virus.  Infected cells were cultured for 4 days 
at 37°C and 5% CO2, after which luciferase activity was measured as described.  FACS 
analysis of CCR5 and CD4 expression was carried out the day of infection on cells that 
were plated in 6 well plates and maintained in an identical manner. 
 
FACS analysis of CD4, CCR5, CXCR4 and GFP expression 
CD4+ lymphocytes were pelleted (250xg for 5 minutes), washed with FACS 
buffer (PBS containing 1% fetal bovine serum and 0.1% NaN3), resuspended in 50 µl of 
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FACS buffer and stained with 1 µl of mAbs to CD4 (clone RPAT-4- Fluorescein 
isothiocyanate [FITC]-conjugated), CCR5 (clone 2D7-phycoerythrin [PE]-conjugated), 
and CXCR4 (clone 12G-PE-Cy5-conjugated) (all from BD Biosciences, San Jose, CA).  
Fluorescence minus one controls as well as cells stained with single antibodies were 
carried out in parallel.  Cells were incubated at room temperature in the dark for 30 
minutes then washed and resuspended in FACS buffer at 106 cells per ml.  Cells were 
analyzed by a FACS Calibur flow cytometer (BD) using Cell Quest (BD) and FloJo 
software (Tree Star Inc, Ashland, OR).  
 To determine the expression of CD4 and wt or mutant CCR5 on transfected 293 
cells, cells were detached by incubation for 10 minutes in PBS containing 2mM EDTA, 
pelleted, washed in FACS buffer then stained with CD4 FITC, CCR5 PE (clone 2D7) and 
CCR5 (clone 3A9-Allophycocyanin [APC]-conjugated) as mentioned.  Cells stained with 
single antibodies were carried out in parallel, and fluorescence was measured and 
analyzed as described.   For CD4 and CCR5 quantification on 293 Affinofiles, cells were 
detached as previously mentioned then stained with the CCR5 PE mAb or with CD4 PE 
mAb (clone S3.5-Invitrogen, Carlsbad, CA) as described. Fluorescence was measured 
and analyzed by FACS as described, and CD4 and CCR5 binding sites were quantified 
using FloJo Software by comparing the average mean fluorescence intensity of stained 
cells to a standard curve created using PE-labeled beads with four distinct, defined 
quantities of fluorophores (QuantiBrite Beads, BD) as described (Davis et al., 1998).  For 
detection of GFP expression after CD4+ T cell infection by HIV-1 pseudotypes, cells 
were washed and resuspended in FACS buffer as described 3 days post-infection and 
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analyzed for GFP fluorescence using the FACS Calibur flow cytometer and FloJo 
software. 
Statistical analysis and PSSM matrix scoring 
 Statistical analysis was performed using GraphPad Prism 4 software.  The EC50 
values for M657 and Maraviroc were determined using a sigmoidal dose response 
equation.  Correlations were derived by linear regression analysis, and correlation 
coefficients and p-values were determined using a 2-tailed Pearson test. 
The predicted viral phenotype of R5X4 Envs used in this study was determined 
using the position-specific scoring matrix (PSSM) program 
(http://indra.mullins.microbiol.washington.edu/webpssm/).  The PSSM algorithm 
compares amino acids at each position within the V3 of submitted envelopes to the 
corresponding residues from a database of Envs experimentally analyzed for coreceptor 
use (R5/X4 matrix) or viral isolates tested for T cell line syncytium-inducing capacity 
(SI/NSI matrix) as previously described (Jensen et al., 2003).   
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Chapter III - Identification of the cellular factors that regulate CCR5 
use on CD4+ lymphocytes by R5X4 HIV-1 
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Introduction 
Pathogenesis by R5X4 viruses is linked to CXCR4 use in several models.  
Infection and depletion of lymphocytes in human lymphoid tissue infected ex vivo by 
R5X4 HIV-1 is completely blocked by the CXCR4 antagonist AMD3100 (Glushakova et 
al., 1999; Malkevitch et al., 2001).  Moreover, infection of rhesus macaques with 
SIV/HIV (SHIV) chimeras carrying R5X4 envelopes induces a disease course similar to 
infection with X4 HIV-1 in humans (Nishimura et al., 2005; Nishimura et al., 2004).  In 
light of these findings, our lab attempted to define the coreceptors used on CD4+ 
lymphocytes by R5X4 HIV-1 in vitro using prototype viruses.   Although infection was 
quite robust on untreated lymphocytes, we were surprised to see almost no CCR5-
mediated infection of lymphocytes by prototype R5X4 viruses when CXCR4 was 
blocked. Yet, R5 viruses used lymphocyte CCR5 for entry under the same conditions, 
showing that R5X4 HIV-1 was severely impaired in the use of an otherwise functional 
coreceptor.  Conversely, when CCR5 was blocked, infection was not affected, indicating 
that R5X4 HIV-1 entry into CD4+ lymphocytes occurred almost exclusively through 
CXCR4 (Yi et al., 1999; Yi, Shaheen, and Collman, 2005).  In contrast to those data, 
other studies have suggested that lymphocyte CCR5 can be used by some R5X4 strains 
(Ghezzi et al., 2001; Gray et al., 2006).  
 Thus, while CCR5 appears to be the secondary entry pathway into CD4+ 
lymphocytes by R5X4 HIV-1, it is unclear whether R5X4 viruses vary in their CCR5 use 
and if entry mediated by this coreceptor can substantially contribute to T cell infection.  
CCR5 expression is one factor that might regulate coreceptor use on CD4+ lymphocytes 
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by R5X4 HIV-1.  CCR5 is expressed at low density on a small percentage of CD4+ 
lymphocytes, and low levels of receptor expression in other cell types has been associated 
with cell type-specific restriction of infection.  Macrophages are poorly infected by many 
lab-adapted X4 strains, but increasing CXCR4 expression increases macrophage 
susceptibility to infection by these viruses (Tokunaga et al., 2001).   Furthermore, studies 
focused on coreceptor use by viruses from different tissues revealed that M-tropic R5 
Envs were uncommon in blood, semen and lymph nodes.  Interestingly, these Envs were 
able to mediate infection of CD4+ lymphocytes at levels similar to M-tropic R5 Envs 
recovered from brain.  The lack of M-tropism by peripheral R5 Envs was associated with 
an inability to infect cells expressing low levels of CD4 and CCR5 (Peters et al., 2004; 
Peters et al., 2006).  
 In this chapter, I examine the diversity among R5X4 HIV-1 in the extent to which 
CCR5 can be used for infection of lymphocytes, and identify factors that regulate 
coreceptor use by these viruses on CD4+ lymphocytes.   To do this, I assembled a diverse 
panel of R5X4 envelope clones, determined the extent to which CCR5 contributed to 
infection of CD4+ lymphocytes by pseudotyped luciferase reporter viruses, and examined 
the effect of increasing CCR5 expression on lymphocyte coreceptor use.  My findings 
show a limited range of lymphocyte CCR5 use among the R5X4 viruses with some 
viruses exhibiting extremely poor use of this coreceptor.  Regardless of CCR5 use, 
CXCR4 remained the predominant coreceptor used by all viral clones.  I also found that 
increasing CCR5 expression on lymphocytes could markedly enhance entry mediated by 
this coreceptor for most (but not all) R5X4 viruses.  Thus, low CCR5 expression on 
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CD4+ lymphocytes is responsible for limiting and, in some cases, restricting CCR5-
mediated infection of T cells by R5X4 HIV-1 isolates.  
Results 
A spectrum of restricted CCR5-mediated entry into CD4+ lymphocytes exists among 
R5X4 viruses 
 In order to examine the diversity in primary cell coreceptor utilization among 
R5X4 HIV-1 and facilitate the identification of factors that influence primary cell 
coreceptor use, we assembled a panel of diverse R5X4 env clones derived from divergent 
sources.  Luciferase reporter viruses were generated that carried primary isolate R5X4 
HIV-1 envelope clones from three different infected individuals (DR, C2, NR), using 
several individual Envs from within each swarm (Gorry et al., 2002b; Gray et al., 2006; 
Ray et al., 2007).  We also studied three widely used prototype R5X4 clones (89.6, DH12 
and R3A) which are also primary isolate-derived (Collman et al., 1992; Meissner et al., 
2004; Shibata et al., 1995), along with control R5 and X4 Envs Bal and Tybe, 
respectively (Hwang et al., 1991; Yi et al., 2003a).  Of note, 89.6, DH12 and NR envs 
were derived from late-stage AIDS patients (Collman et al., 1992; Ray et al., 2007; 
Shibata et al., 1995), which is the most common situation in which these variants are 
seen.  R3A was an unusual R5X4 isolate in that is was obtained at the time of 
seroconversion from an individual infected via intravenous drug use who exhibited rapid 
disease progression (Meissner et al., 2004; Yu et al., 1998), whereas C2 and DR were 
isolated from two CCR5-null individuals (Gray et al., 2006).  Dual CCR5 and CXCR4  
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Figure 3.1. Coreceptor use on U87 indicator cells by HIV-1 pseudotype viruses.   
 U87 indicator cells expressing only CD4, CD4 and CCR5, or CD4 and CXCR4 were infected with HIV-1 
luciferase reporter viruses pseudotyped with primary isolate envelopes (C2, DR, NR), prototype R5X4 
envelopes (89.6, DH12 or R3A), R5 (Bal or JRFL) or X4 envelopes (Tybe) as controls.  Three days later, 
infection levels were determined by measuring luciferase activity in cell lysates. The results are expressed 
in relative light units (RLUs) and represent means +/- standard error (SEM) for two experiments performed 
in triplicate. 
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Figure 3.2. CXCR4 is the principal coreceptor on PHA/IL-2 stimulated CD4+ lymphocytes for R5X4 
HIV-1 primary and prototype strains.   
CD4+ T cells were stimulated with PHA for 3 days then treated for 1 hour before infection with or without 
the CXCR4 blocker AMD3100 (5µg/ml; “CCR5 pathway”), CCR5 blocker M657 (5µM; “CXCR4 
pathway”) or both (“neither pathway”).  Cells were then infected with HIV-1 luciferase reporter viruses in 
the continued presence of coreceptor blockers and maintained with IL-2 (10 U/ml).   Four days post 
infection, viral entry was determined by luciferase activity in cell lysates.  Results shown for each virus are 
presented in RLUs (A) and as a percentage of the RLUs seen in the absence of coreceptor blockers (B). 
Data are means +/- SEM of three experiments using lymphocytes from different donors, each done in 
duplicate. 
A 
B 
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use for each virus was confirmed by infecting U87 cells that expressed CD4 and either 
CCR5 or CXCR4 (Fig. 3.1).   
 In order to determine coreceptor use by these viruses on primary lymphocytes, 
CD4+ T cells were infected in the absence or presence of CCR5 or CXCR4 antagonists 
M657 and AMD3100, respectively (Fig. 3.2).  As expected, Bal was completely inhibited 
by the CCR5 antagonist M657 and Tybe by the CXCR4 antagonist AMD3100.  When 
CD4+ lymphocytes were infected with R5X4 pseudotypes, a different pattern was 
evident.  All R5X4 strains were markedly inhibited by CXCR4 blockade, whereas CCR5 
blocking had no detectable effect.  For all R5X4 strains, however, the addition of M657 
to AMD3100 further reduced entry levels (Fig. 3.2a).  These results indicate that all 
R5X4 viruses tested entered CD4+ lymphocytes through both CXCR4 and CCR5, but 
that infection through CCR5 was markedly less than that through CXCR4, and played 
little, if any, additional role when both coreceptors were available.  
To quantitate the relative contribution of each coreceptor to infection of CD4+ 
lymphocytes, the luciferase levels in the presence of coreceptor antagonists were 
normalized to the total infection capacity for each virus in untreated cells (Fig. 3.2b).   
Blocking CCR5 alone had no inhibitory effect on infection for any of the viruses.  
However, CXCR4 blocking, when compared to dual coreceptor blocking, revealed 
CCR5-mediated infection that ranged from ≤10% for the three prototype strains and two 
of the DR primary isolate Envs, to 50% of untreated levels for the C2-16 primary isolate 
Env.  Thus, CXCR4 is the predominant coreceptor used by R5X4 viruses to infect CD4+ 
lymphocytes.  However, some entry can be mediated by CCR5, and that proportion varies 
between isolates indicating a spectrum of lymphocyte CCR5 use.  
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Figure 3.3. CCR5 upregulation on CD4+ lymphocytes increases the proportion of R5X4 infection 
mediated by CCR5.  
CD4+ lymphocytes were CD3/CD28 costimulated for three days and then infected with HIV-1 luciferase 
pseudotype viruses (A) or cultured with IL-2 for 10 additional days to upregulate CCR5 expression prior to 
infection (B).  Infections were carried out with or without AMD3100, M657 or both antagonists to block 
CXCR4 and/or CCR5.  Four days later, infection was determined by luciferase activity in cell lysates.  
Entry was normalized as a percentage of the RLUs seen in the absence of coreceptor blockers for each 
virus.  Data are means +/- SEM of three experiments using lymphocytes from different donors, each done 
in duplicate. 
A 
B 
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CCR5 upregulation on CD4+ lymphocytes increases the proportion of R5X4 HIV-1 entry 
mediated by CCR5 
 These data indicate that CCR5-mediated infection of CD4+ lymphocytes by many 
R5X4 HIV-1 is restricted (Fig. 3.2), yet all viruses in question can use this coreceptor to 
readily infect indicator cells such as U87 CD4/CCR5 cells (Fig. 3.1).  CCR5 on indicator 
cells is typically over-expressed, however, while peripheral blood lymphocytes express 
CCR5 at low density and on a minority of cells (Lee et al., 1999b; Wu et al., 1997).  We 
therefore sought to test whether low levels of CCR5 expression were an obstacle to 
efficient CCR5 use on CD4+ lymphocytes by R5X4 viruses, and how CCR5 expression 
levels regulated pathway-specific R5X4 lymphocyte entry.  To address the role of CCR5 
expression, CD4+ lymphocytes were infected with HIV-1 luciferase pseudotype viruses 
immediately after 3 days of CD3/CD28 costimulation, or after 10 additional days of 
culture with 300 U/ml of IL-2, which has been shown to upregulate lymphocyte CCR5 
(Creson et al., 1999; Yang et al., 2001).  Infections were performed in the presence or 
absence of CCR5 and CXCR4 antagonists to determine proportional use of each entry 
pathway.  Coreceptor expression as determined by surface staining indicated that few 
CD4+ lymphocytes were CCR5+, whereas 20-40% had detectable CCR5 after prolonged 
culture.  In addition to the increase in percentage of cells within the CCR5+ gate, the 
mean fluorescence intensity (MFI) of cells within the CCR5 gate increased as well 
(approximately 2-fold).  In contrast, the percentage of cells expressing CXCR4 decreased 
to a modest degree but remained higher after culture with IL-2 (50-70%).   
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 As shown in Fig. 3.3a, CCR5 use by R5X4 HIV-1 was restricted in day 3 
CD3/CD28-stimulated CD4+ lymphocytes, with CXCR4 being the predominant pathway 
used for entry.  However, there was a modest spectrum of CCR5 use similar to that seen 
in PHA-stimulated lymphocytes (Fig. 3.2).  In contrast, CCR5 upregulation following 10 
days of IL-2 stimulation dramatically increased the proportion of infection mediated by 
CCR5 for most R5X4 viruses tested, with the exception of 89.6, which remained nearly 
completely CXCR4 dependent (Fig. 3.3b).   
 Nevertheless, for those viruses that did increase the proportion of entry mediated 
by CCR5, CXCR4 remained the predominant coreceptor used for infection of day 13 
CD4+ lymphocytes by most R5X4 strains.  Exceptions to this coreceptor usage pattern 
were seen in the two C2 Envs (C2-16 and C2-22) for which CCR5 consistently mediated 
an equal or greater proportion of entry than did CXCR4 on CCR5-upregulated CD4+ T 
cells (Fig. 3.3b).  VSV-G pseudotypes, used as a control, showed no change in luciferase 
expression from day 3 to day 13 cells (data not shown). 
 
The percentage of CD4+ lymphocytes infected through each coreceptor is modulated 
following CCR5 upregulation 
In addition to total infection levels within the cultures, we also aimed to define the 
contribution of each pathway to infection of individual CD4+ T lymphocytes following 
CCR5 upregulation.  CD4+ lymphocytes were cultured for 3 or 13 days as described 
above to establish standard or high CCR5 expression conditions, respectively, and then 
infected with HIV-1 Env pseudotype virions carrying a GFP reporter gene.  Infection-
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mediated GFP expression therefore enabled per-cell analysis of infection based on GFP 
expression as determined by FACS.   As with luciferase infection, addition of both CCR5 
and CXCR4 antagonists completely blocked GFP expression (data not shown).   
 As shown in Fig. 3.4a, CCR5-mediated entry into day 3 CD4+ lymphocytes 
resulted in a low percentage of GFP-positive infected cells.  This value ranged from 
barely detectable (DH12) to ~5% (C2-16 and the R5 Env JRFL).  While this result is 
concordant with the low percentage of cells positive for CCR5 expression by FACS, it 
was interesting to note that the fraction of GFP+ cells for C2-16 and JRFL often 
exceeded the proportion that were CCR5+ by FACS.  Entry by these viruses was clearly 
mediated by CCR5, however, since infection was blocked by M657 or Maraviroc (data 
not shown).  This finding indicates that susceptibility to infection by efficient CCR5-
using Envs can be a more sensitive indicator of CCR5 expression than immunostaining, 
and thus, these isolates can use CCR5 at levels that are below the threshold of detection 
by FACS.  Furthermore, the fact that some strains can exploit CCR5 to infect what 
appear to be CCR5-negative CD4+ T cells by FACS indicates that, following 
upregulation, the apparent increases in percentage of CCR5+ cells also reflects increased 
CCR5 expression levels by cells that are initially CCR5+ but at a level below the 
threshold detectable by flow cytometry.  
When CCR5 was upregulated on CD4+ lymphocytes by prolonged culture in IL-2 
(Fig. 3.4a, right), the percentage of GFP+ cells infected through CCR5 increased 
dramatically for the R5 isolate JRFL.  Similarly, the percentage of GFP+ cells infected 
through CCR5 also increased for R5X4 viruses following CCR5 upregulation, although 
these percentages remained less than that for JRFL.  Infection with VSV-G pseudotypes,  
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Figure 3.4.  Stimulation-dependent changes in coreceptor expression affect the percentage of CD4+ 
lymphocytes infected via each pathway.  
CD4+ lymphocytes were infected with HIV-1 GFP pseudotype viruses after 3 days of CD3/CD28 
costimulation or following an additional 10 days of culture with IL-2 to upregulate CCR5.  Cells were 
incubated with coreceptor antagonists for 1 hour prior to and throughout the infection to define the pathway 
of entry.  CCR5 and CXCR4 expression were analyzed by FACS on the day of infection, and four days 
later, infected cells were determined by FACS analysis for GFP expression.  Data indicate the percentage 
of GFP+ cells infected through CCR5 (A) or CXCR4 (B) at day 3 and day 13 after isolation, and are 
representative of three independent experiments using cells from different donors.  The percentage of cells 
expressing CCR5 (A) and CXCR4 (B) at the time of infection is indicated by an asterisk (*). 
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used as a control for possible effects independent of coreceptor-mediated entry, showed 
no change in infection (54±6% GFP+ on day 3 cells and 44±8% on day 13 cells; data not 
shown).  Thus, both R5X4 and R5 Envs are highly dependent on CCR5 expression levels, 
although R5 JRFL is more efficient at exploiting limiting levels than R5X4 Envs (Fig. 
3.4a).  
In contrast to CCR5, CXCR4 levels typically decreased somewhat from day 3 to 
day 13, and this was associated with a modest decrease in the percentage of cells infected 
via CXCR4 for the R5X4 viruses tested, as well as the X4 strain Tybe (Fig. 3.4b). 
 
Coreceptor-dependent R5X4 entry following lentiviral vector CCR5 over-expression 
 Although 10 days in culture with IL-2 upregulated CCR5 levels and modulated 
coreceptor utilization, we considered the possibility that the extended period in vitro 
could also effect other factors that impact infection, despite the lack of changes in VSV-
G pseudotype infection.  For that reason, we used a second approach to upregulate CCR5.  
CD4+ lymphocytes were transduced after 3 days of PHA stimulation with a lentiviral 
vector expressing CCR5 or a mutated version of the coreceptor that is not expressed on 
the cell surface.  CCR5 levels on transduced cells were measured by FACS, and cells 
were infected with prototype R5X4 Env luciferase viruses in the presence or absence of 
AMD3100.  Transduction with the CCR5 vector increased the proportion of CCR5+ cells 
to 18-70% of CD4+ lymphocytes compared with 1-19% of cells transduced with a 
control vector (Fig. 3.5), and the MFI of CCR5+ increased as well (fold increase of 
2.9±0.9; data not shown).  CCR5 over-expression led to a marked increase in entry 
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mediated by CCR5 for R5X4 pseudotypes R3A and DH12 compared to control vector-
transduced cells (Fig. 3.5).  In contrast, entry mediated by CCR5 increased only 
marginally for strain 89.6.  CCR5 transduction had no impact on the MFI of CD4 or 
CXCR4 expression and did not impact infection by the X4 virus Tybe (data not shown).  
Results from the lentiviral vector CCR5 over-expression studies are similar to those 
following stimulation-induced upregulation (Fig. 3.3), supporting the notion that entry as 
measured here reflects changes in coreceptor expression and not other features of the cell 
condition that might modulate infection. 
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Figure 3.5. Lentiviral over-expression of CCR5 increases the proportion of R5X4 entry mediated by 
CCR5 on CD4+ lymphocytes.   
CD4+ lymphocytes were stimulated with PHA for 3 days, transduced with either control or CCR5-
expressing lentiviruses, and maintained in the presence of IL-2.   Two days post-transduction, cells were 
pretreated for 1 hour with CXCR4 blocker AMD3100 and infected with HIV-1 luciferase pseudotypes in 
the continued presence of blocker.  Infection was determined by luciferase activity in cell lysates four days 
later.  The results are shown as the proportion of CD4+ lymphocyte infection mediated through CCR5 for 
R3A (A), DH12 (B) and 89.6 (C) on the Y-axis, plotted against the percentage of CD4+ lymphocytes that 
express CCR5 after transduction with a control or CCR5 expression vectors.  Data are from three 
independent experiments using cells from different donors.   
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Conclusions 
Coreceptor use and target cell tropism are important determinants of HIV-1 
transmission and pathogenesis.  In previous studies of primary cell tropism and 
coreceptor use by prototype R5X4 HIV-1 strains, we found that these viruses could use 
CCR5 and CXCR4 to infect macrophages, but in CD4+ lymphocytes, CXCR4 was the 
predominant entry pathway while CCR5 was used poorly, if at all.  Here I sought to 
determine, employing a variety of dual-tropic isolates from disparate sources, whether 
R5X4 strains vary in their ability to use CCR5 on lymphocytes, and what factors were 
responsible for determining use of this pathway.   
My findings reveal limited CCR5-mediated infection of CD4+ T cells by the 
R5X4 strains tested, which did not substantially contribute to overall infection levels 
when CXCR4 was available.  However, a spectrum existed among the R5X4 variants in 
the extent to which lymphocyte CCR5 could be used if CXCR4 was not available.  
Notably, while one R5X4 virus could reach CCR5-mediated infection levels approaching 
half that of untreated cells, R5X4 strains with marginal CCR5 use (≤ 10% of total entry) 
were more common.  CCR5 is expressed at low levels on CD4+ lymphocytes.  My results 
show that increasing CCR5 expression increased CCR5 use on CD4+ T cells by nearly 
all viruses, including R5X4 strains that were among the most restricted in the use of this 
coreceptor.  However, 89.6 remained unable to use lymphocyte CCR5 even after 
increasing CCR5 expression on these cells.  Thus, we conclude that CCR5 expression on 
CD4+ lymphocytes is an important regulator of the use of this coreceptor by many R5X4 
viruses, but that other obstacles to lymphocyte CCR5 use may exist. 
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Even for R5X4 viruses with relatively greater lymphocyte CCR5 use, blocking 
this pathway had no impact on CD4+ T cell infection, as entry through CXCR4 alone 
was equivalent to infection when both coreceptors were available.  CXCR4 is expressed 
on the majority of peripheral blood CD4+ lymphocytes, whereas CCR5 is expressed on a 
smaller subset of cells (Lee et al., 1999b; Ostrowski et al., 1998; van Rij et al., 2000; Wu 
et al., 1997).  Most cells that are CCR5+ also express CXCR4; so blocking CCR5 may 
have little net effect on infection because entry can still occur through CXCR4.  
Conversely, since many CXCR4+ lymphocytes do not express CCR5, entry in the 
presence of CXCR4 blockers should be representative of the subset of cells that express 
CCR5.  As demonstrated by my findings following CCR5 upregulation, increasing the 
subset of cells that express this coreceptor contributes to the increased proportion of 
infection mediated by CCR5.  
If CCR5 use was determined solely by the percentage of lymphocytes that express 
this coreceptor, then CCR5-mediated infection should be equivalent for all R5X4 variants 
(and should be equivalent to infection by R5 variants), yet that was not observed.  CCR5 
use on lymphocytes varied among the R5X4 viruses, and this variation appeared to be 
related to the efficiency of interaction with CCR5.  The percentage of lymphocytes 
infected using CCR5 by C2-16, the R5X4 strain with the greatest CCR5 use, were higher 
than the percentage of CCR5+ cells measured by FACS suggesting this virus can detect 
CCR5 better than some CCR5 specific antibodies.  Furthermore, the two R5X4 strains 
with the greatest CCR5 use at endogenous levels were also the only viruses that showed a 
shift in preferential coreceptor use to CCR5 after upregulation of this coreceptor. This 
implies the R5X4 envs differ in the efficiency of interaction with CCR5 and the increased 
54 
CCR5 density following CCR5 over-expression was a critical factor in the increased 
CCR5-mediated infection of lymphocytes by R5X4 viruses.  It is not clear from this 
study if CCR5 density or the percentage of CCR5+ cells plays a larger role in regulating 
use of this coreceptor on lymphocytes by R5X4 viruses. 
The pattern of strain-dependent differences in the ability to use CCR5 on 
lymphocytes also strongly suggests a role for Env in regulating use of this coreceptor on 
lymphocytes by R5X4 viruses.  Although CCR5 use by most of the viruses with 
extremely poor use of this coreceptor could be improved by increasing CCR5 expression, 
this was not the case for 89.6.  Regardless of the method or magnitude of CCR5 over-
expression, the virus remained extremely dependent on CXCR4 for infection.  The nature 
of restricted CCR5 use by this virus is unclear, but results following CCR5 upregulation 
indicate CCR5 levels alone are not responsible for impaired lymphocyte CCR5 use by the 
89.6 Env. 
In summary, this study confirms with a panel of primary and prototype R5X4 
HIV-1 variants that these strains are highly skewed towards CXCR4 use for entry into 
CD4+ T cells.  However, there does exist a range among the isolates in the relative ability 
to use CCR5 on primary lymphocytes.  CCR5 use by nearly all R5X4 viruses could be 
improved by CCR5 over-expression in lymphocytes, and this was sufficient to eliminate 
the barrier to CCR5 use for most, albeit not all, of the R5X4 isolates.  These results 
indicate low lymphocyte CCR5 expression is a factor in the restriction to R5X4 entry 
through this pathway, although additional obstacles to primary cell coreceptor use exist.  
Better understanding of the viral and cellular factors that control coreceptor use by HIV-1 
strains is critical to understanding the impact of viral evolution on target cell tropism.  
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Chapter IV - Efficiency of the Env-CCR5 interaction determines the 
spectrum of CCR5 use on CD4+ lymphocytes by R5X4 HIV-1 
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Introduction 
 HIV-1 Envs can differ in the ability to fuse viral and cellular membranes, and this 
variation in entry efficiency can lead to differences in infectivity and pathogenicity 
between viral strains.  Longitudinal studies of HIV-1 infected patients that harbor only 
R5 viruses show that isolates from advanced stages of disease replicate to higher titers 
and are more cytopathic than isolates recovered during the asymptomatic phase of 
infection.  Subsequent experiments using chimeric viruses indicated that greater 
infectivity of late R5 isolates was Env-dependent (Olivieri et al., 2007; Repits et al., 
2005).  Animal models of HIV-1 infection also suggest links between entry efficiency 
and pathogenesis.  In vivo passage of SHIV-1 89.6 in rhesus macaques resulted in a 
variant that aggressively depleted CD4+ lymphocytes and caused much more rapid 
disease progression than infection with the parental virus (Karlsson et al., 1997).  The 
difference in pathogenicity between these variants was associated with higher levels of 
replication on rhesus PBMCs and greater ability to induce syncytia by the passage virus.  
In these studies, the phenotypic differences between the parental and passaged SHIV-1 
were dependent on the viral Env (Karlsson et al., 1998).  
 Env-coreceptor interactions and receptor density both influence entry efficiency. 
Changes in entry efficiency that result from differences in coreceptor binding or 
coreceptor expression level can impact sensitivity to entry inhibitors.  Indeed, mutations 
that increase coreceptor binding and elevate CCR5 expression are both associated with 
reduced sensitivity to entry inhibitors and faster rates of Env-dependent membrane fusion 
(Heredia et al., 2007; Reeves et al., 2002).  One study reported R5 Envs with lower 
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CCR5 affinity require higher CCR5 levels for infection (Gorry et al., 2002a).  This 
observation implies that these two factors have an interdependent affect on viral entry, 
and it suggests that increased coreceptor expression may enhance entry for viruses with 
inefficient Env-coreceptor interactions. 
  R5X4 viruses are more sensitive to CCR5 antagonists than R5 viruses (Yi, 
Shaheen, and Collman, 2005), and in chapter 3, I presented results that showed restricted 
lymphocyte CCR5 use by R5X4 variants could be rescued by increasing CCR5 
expression.  These results imply that R5X4 viruses have inefficient interactions with 
CCR5, and these interactions contribute to impaired lymphocyte CCR5 use by some 
R5X4 viruses.  I also observed a spectrum of CCR5 use by R5X4 strains on CD4+ T cells 
at endogenous CCR5 levels.  Differences in the Env-CCR5 interaction between R5X4 
strains may also account for the range of lymphocyte CCR5 use seen among the viruses 
in this group. 
 Therefore, in this chapter I examine the efficiency of the R5X4 HIV-1 Env 
interaction with CCR5, and determine whether differences in this interaction influence 
lymphocyte CCR5 use by these viruses.  To do this, I measured the sensitivity of each 
R5X4 virus to entry inhibition by antibodies, CCR5 antagonists and the fusion inhibitor 
T20.  Overall, my results show that R5X4 strains differed in their sensitivity to these 
agents.  Furthermore, I discovered a significant correlation between greater CCR5 use on 
lymphocytes and increased resistance to inhibition by antibodies or antagonists; however, 
there was no relationship between lymphocyte CCR5 use by R5X4 viruses and sensitivity 
to T20.  I also assessed the impact of CCR5 density on infection by various R5X4 strains 
using Affinofile cells that allow inducible regulation of CCR5 expression.  I found that 
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R5X4 strains with greater lymphocyte CCR5 use were less affected by declining CCR5 
levels.  I also observed a significant positive correlation between the ability to exploit low 
levels of CCR5 on the Affinofile cells and CCR5 use on lymphocytes.  My results 
indicate that the Env-CCR5 interactions regulate CCR5-mediated infection of 
lymphocytes by R5X4 HIV-1, and strain-dependent differences in this interaction are 
responsible for the spectrum of lymphocyte CCR5 use by the R5X4 virus panel. 
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Results 
Resistance to inhibition by ECL2-specific CCR5 mAbs correlates with the capacity of 
R5X4 HIV-1 to use CCR5 for lymphocyte infection  
Previous studies comparing CCR5 use by R5 and R5X4 Envs have suggested that 
R5X4 Envs: i) appear to have a lower affinity for CCR5, ii) are generally more sensitive 
to inhibition by CCR5 antagonists, and iii) are more affected by changes in the structure 
of CCR5 (Cormier et al., 2000; Doranz et al., 1997; Lu et al., 1997; Yi, Shaheen, and 
Collman, 2005; Yi et al., 2003b).  Since R5 strains by definition use CCR5 efficiently for 
lymphocyte entry, our finding that R5X4 strains vary in their capacity to infect primary 
lymphocytes through CCR5 raised the possibility that these strains might also vary in 
their interaction with CCR5.   
 To examine the relationship between Env-coreceptor interactions and lymphocyte 
CCR5 use, we took advantage of CCR5-specific mAbs with well-characterized target 
epitopes (Fig. 4.1) (Blanpain et al., 2002; Lee et al., 1999a).  U87/CD4/CCR5 cells were 
infected in the presence or absence of mAbs that target epitopes in the amino terminus 
(N-terminal), the second extracellular loop (ECL2) or multiple domains (MD) of CCR5, 
and entry inhibition was determined by normalizing infection levels to those of untreated 
cells.  As shown in Fig. 4.2, both mAbs that targeted CCR5 ECL2 (45531 and MC-1) 
inhibited entry by the R5X4 viruses.  Infection levels were reduced 15-70% by mAb 
45531 and 30-90% by MC-1.  Treatment with 2D7, another ECL2-directed mAb, 
completely inhibited infection by all viruses, even at four-fold lower concentrations (data 
not shown).  Importantly, R5X4 Envs that were better able to use lymphocyte CCR5 for  
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Figure 4.1. Antibody epitopes on CCR5.   
The antibody binding sites for CCR5 antibodies CTC8 (red), 2D7 (blue), MC-1 (green) and 45531 (purple) 
are shown within shaded squares.  The epitope for multi-domain antibody 45523 is discontinuous and is not 
shown. 
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Figure 4.2. CCR5 use on CD4+ lymphocytes correlates with resistance to inhibition by ECL2 mAbs.  
 U87/CD4/CCR5 cells were treated for 1 hour with or without 10 µg/ml of CCR5-specific mAbs then 
infected with HIV-1 luciferase pseudotype viruses in the continued presence of mAb.  Three days later, 
infection was determined by luciferase activity in cell lysates and normalized to luciferase activity in 
untreated cells.  Each symbol represents an individual R5X4 virus, and results are presented as the 
proportion of total lymphocyte entry mediated by CCR5 (from Fig. 3.2b) on the X-axis versus the 
U87/CD4/CCR5 infection that occurred in the presence of CCR5 mAbs (A) on the Y-axis.  Data are means 
for three experiments each carried out in duplicate. 
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entry were blocked less efficiently than those viruses that used the pathway poorly, as 
shown by the significant correlation between lymphocyte CCR5 use and infection in the 
presence of ECL2-directed mAbs 45531 and MC-1 (Fig. 4.2).  In contrast to the ECL2-
targeted antibodies, multidomain and N-terminal antibodies (45523 and CTC8, 
respectively) had a marginal or no effect on entry (Fig. 4.2).   
 
Sensitivity to CCR5 antagonists but not a fusion inhibitor correlates with lymphocyte 
CCR5 use by R5X4 HIV-1 
We then turned to small molecule CCR5 antagonists, which are frequently used as 
probes to assess Env-coreceptor interactions.  Sensitivity to CCR5 blockers M657 and 
Maraviroc was determined by infecting U87/CD4/CCR5 cells in the presence of 
increasing concentrations of inhibitor.  Infection by all viruses was extinguished at the 
highest concentrations of each antagonist (data not shown), but there was variation in 
sensitivity to both M657 and Maraviroc, exemplified by differences in antagonist EC50 
values among the R5X4 Envs (Fig. 4.3).  M657 and Maraviroc EC50 values were lower 
for R5X4 Envs with poor lymphocyte CCR5 use, compared to Envs such as C2-16 that 
are better able to use this coreceptor.  Similar to inhibition by ECL2-directed CCR5 
mAbs, M657 and Maraviroc EC50 values correlated with lymphocyte CCR5 use (Fig. 
4.3).  Concordant mAb and antagonist results show a link between lymphocyte CCR5 use 
and sensitivity to blocking among R5X4 HIV-1, and suggest that the variation in CCR5-
mediated infection of lymphocytes results at least in part from differences among these 
strains in the efficiency of interactions with the coreceptor. 
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Figure 4.3. CCR5 use on CD4+ lymphocytes correlates with resistance to inhibition by CCR5 
antagonists but not T20.  
 U87/CD4/CCR5 cells were treated for 1 hour with or without increasing concentrations of M657 or 
Maraviroc then infected with HIV-1 luciferase pseudotype viruses in the continued presence inhibitor.  For 
experiments with T20 increasing concentrations of the drug were added with virus at the time of infection.  
Three days later, infection was determined by luciferase activity in cell lysates and normalized to luciferase 
activity in untreated cells.  Each symbol represents an individual R5X4 virus, and results are presented as 
the proportion of total lymphocyte entry mediated by CCR5 (from Figure 3.2b) on the X-axis versus the 
entry inhibitor EC50 value on the Y-axis.  Data are means for three experiments each carried out in 
duplicate. 
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 The fusion inhibitor T20 binds to the HR1 region of gp41 and prevents the 
conformational changes that lead to membrane fusion.  To determine whether R5X4 
viruses differ in sensitivity to T20, U87/CD4/CCR5 cells were infected with HIV-1 in the 
presence of increasing concentrations of drug.  Infection by all viruses was inhibited at 
the highest concentration of T20 (data not shown).  While there was a range of T20 EC50 
values that were similar for most viruses, DR-17 was substantially less sensitive to the 
drug with an EC50 value that was over two logs higher than the median EC50 value of 
the group (data not shown).  Consequently, this virus was excluded from subsequent 
analysis.  Unlike the CCR5 antagonists, viruses with greater lymphocyte CCR5 use were 
not less sensitive to inhibition by T20, and there was no correlation between T20 EC50 
value and CCR5 use on lymphocytes by R5X4 viruses (Fig. 4.3).   Thus, differences in 
the efficiency of fusion do not appear to impact lymphocyte CCR5 use by R5X4 viruses. 
Greater lymphocyte CCR5 use is associated with reduced sensitivity to CCR5 density for 
infection of Affinofile cells  
 Increasing CCR5 expression on CD4+ lymphocytes increased the proportion of 
infection mediated by CCR5 for R5X4 viruses, suggesting inefficient use of endogenous 
CCR5 might be linked to sensitivity to coreceptor expression levels.  To further address 
the interplay between CCR5 expression and R5X4 infection, we used 293 Affinofile cells 
(Fig. 4.4), a cell line in which expression of CD4 and CCR5 can be regulated precisely 
and independently by Minocycline and Ponasterone, respectively (Johnston et al., 2009; 
Lassen et al., 2009).  The number of CD4 and CCR5 antibody binding sites (ABS) per 
cell can be determined for each inducer combination using quantitative FACS analysis.   
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Inducible CD4 and CCR5 Affinofile expression system.   
Affinofile cells were created by transfecting 293 cells with plasmids expressing CD4 and CCR5 along with 
separate plasmids expressing inducible transcription factors that are responsive to minocycline and 
ponasterone. Addition of increasing concentrations of minocycline or ponasterone increases CD4 or CCR5 
expression, respectively (A). Addition of different combinations of each inducer allows independent 
regulation of CD4 or CCR5 levels, which can be quantitated by FACS (B).  Figure courtesy of Johnston, S. 
et al. J. Viro. 2010 
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Induction of Affinofile cells resulted in CD4 expression levels that ranged from 3,000 to 
200,000 ABS per cell and CCR5 levels from 1,000 to 50,000 ABS per cell.  Importantly, 
these levels encompass the physiologically relevant range of CD4 and CCR5 levels 
reported on stimulated CD4+ lymphocytes of 65,000-100,000 and 500-7,000 molecules 
per cell, respectively (Lee et al., 1999b).  Therefore, we chose to examine the sensitivity 
of R5X4 HIV-1 infection to CCR5 expression levels in Affinofile indicator cells by 
analyzing the effect of physiologically relevant CD4 expression levels (~83,000 
molecules/cell).  Cells were maintained with a stable concentration of CD4 inducer and 
different concentrations of CCR5 inducer, and infected with luciferase pseudotype 
viruses at the same time that receptor expression levels were confirmed by FACS.  
Luciferase levels produced at each CCR5 density were normalized to luciferase activity 
in cells with the highest density of CCR5.   
As shown in Fig. 4.5a, at a stable level of CD4 expression, luciferase virus 
infection was reduced for all R5X4 viruses as CCR5 density decreased.  However, there 
were marked differences in the response to declining CCR5 levels.  R5X4 Envs C2-16 
and NR10 were least affected by declining CCR5 expression, showing 60 to 80% of 
maximal infection even at the lowest CCR5 density.  A second group of R5X4 viruses, 
R3A, DR17 and DH12, were more impaired by low CCR5 expression, achieving 35-45% 
of maximal infection at the lowest CCR5 expression level tested.  89.6 was the R5X4 
virus most affected by decreasing CCR5 expression, at the lowest density of CCR5 
expression reaching only 25% of its maximal level of infection (Fig. 4.5a).  Thus, R5X4 
HIV-1 display a spectrum in their ability to use diminishing levels of CCR5 on Affinofile 
cells in the presence of physiologically relevant CD4 levels. 
  
  
A. 
B. 
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Figure 4.5.  Efficiency of CCR5 use on Affinofile cells correlates with CCR5 use on CD4+ 
lymphocytes by R5X4 HIV-1.   
Affinofile cells were induced to express a fixed level of CD4 (83,000 antibody binding sites (ABS)/cell) 
and varying levels of CCR5, then infected with HIV-1 luciferase pseudotypes in the presence of AMD3100 
to block endogenous CXCR4.  Infection was quantified 4 days later by luciferase activity in cell lysates.  
The results are shown as the luciferase levels at each CCR5 density normalized to infection levels on cells 
expressing the maximum density of CCR5 (A). The relationship between normalized infection of Affinofile 
cells expressing the lowest density of CCR5 and the proportion of total CD4+ lymphocyte infection that is 
mediated by CCR5 (from Fig. 3.2b) for each R5X4 Env pseudotype is also shown (B). 
B 
A 
Rsq = 0.9437 
p < 0.005 
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Ability to use CCR5 on CD4+ lymphocytes by R5X4 HIV-1 correlates with the use of low 
levels of CCR5 on 293 Affinofile cells 
We then asked if there was an association between R5X4 use of lymphocyte 
CCR5 and entry into Affinofile cells expressing CCR5 at the lowest density (Fig. 4.5a).  
Overall, there was a strong correlation for R5X4 HIV-1 between the proportion of CD4+ 
lymphocyte entry mediated by CCR5 and the ability to infect Affinofile cells expressing 
diminishing levels of CCR5 (Fig. 4.5b).  C2-16 and NR-10 used CCR5 on lymphocytes 
more efficiently than other R5X4 viruses and were least sensitive to decreasing levels of 
CCR5 on the Affinofile cells.  Lymphocyte CCR5 use was lowest for 89.6 and infection 
of Affinofile cells was most impaired by decreasing CCR5 levels for this virus.  DR17, 
R3A and DH12 showed an intermediate phenotype in both lymphocyte CCR5 use and 
infection of Affinofile cells expressing low levels of CCR5.  These results confirm that 
there is biological heterogeneity among R5X4 HIV-1, and suggest that strains with 
marginal CCR5 use on lymphocytes are unable to effectively scavenge for CCR5 when it 
is expressed at low density.  
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Conclusions 
 Entry efficiency, which is dependent on Env-coreceptor interactions and 
coreceptor density on target cells, is an important determinant of replication capacity and 
pathogenesis.  Previous work from our lab showed that R5X4 viruses were more sensitive 
to CCR5 antagonists than R5 viruses, and in chapter 3, I described how increasing CCR5 
expression on CD4+ lymphocytes enhanced CCR5 use by viruses with poor use of this 
coreceptor.  Thus, previous reports combined with my recent findings suggested 
inefficient Env-CCR5 interactions may be one mechanism that regulates lymphocyte 
CCR5 use by R5X4 strains.   
 In this chapter, I determined the relationship between the efficiency of CCR5 use 
by R5X4 strains and lymphocyte CCR5 use.  Using sensitivity to entry blocking agents as 
a surrogate marker for the efficiency of CCR5 use, I found that R5X4 viruses were 
markedly inhibited by CCR5 antibodies with ECL2 epitopes but not by other CCR5 
antibodies, and resistance to inhibition correlated with greater lymphocyte CCR5 use.  In 
addition, I found a significant correlation between greater lymphocyte CCR5 use by 
R5X4 strains and resistance to inhibition by CCR5 antagonists, but not the fusion 
inhibitor T20.  I also employed Affinofile cells with regulated levels of CD4 and CCR5 
to examine the impact of CCR5 expression on infection by R5X4 strains.  I discovered 
that decreasing CCR5 expression had the largest impact on infection by viruses that used 
lymphocyte CCR5 poorly, in that strains with greater lymphocyte CCR5 use could better 
exploit low levels of CCR5 on these cells.  From these results, I conclude that the 
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spectrum of lymphocyte CCR5 use by R5X4 HIV-1 is determined by the efficiency of the 
Env-CCR5 interaction. 
 CCR5-mediated infection of CD4+ lymphocytes by R5X4 HIV-1 is relatively 
small in comparison to infection mediated by CXCR4 when that coreceptor is available, 
but the levels of lymphocyte CCR5 use vary among the R5X4 strains.  The results 
outlined here indicate the efficiency of the Env-CCR5 interaction differs between viruses 
and is a principal determinant of the ability to use this coreceptor.  Specifically, viruses 
with more efficient Env-coreceptor interactions are able to use low levels of CCR5 more 
efficiently, suggesting that these viruses require a lower threshold of CCR5 to facilitate 
membrane fusion.  The density of CCR5 expressed on individual CD4+ lymphocytes 
varies (Reynes et al., 2000), and these findings indicate that R5X4 strains with a lower 
CCR5 density threshold can reach higher levels of infection by infecting lymphocytes 
that express minimal levels of CCR5.  Thus, the percentage of CCR5+ CD4+ 
lymphocytes determines the potential levels of CCR5 use, but actual CCR5 use by an 
R5X4 variant is determined by how efficiently its Env interacts with the coreceptor. 
 The results of this study show that CCR5 mAbs with epitopes in ECL2 inhibit 
R5X4 infection, and the extent of this inhibition is associated with the ability to use 
CCR5 on lymphocytes.  This suggests the efficiency of interaction with ECL2 contributes 
to determining lymphocyte CCR5 use by R5X4 strains.  On the other hand, it is also 
possible that these mAbs are affecting interactions with other CCR5 domains, since 
inhibition by an antibody is not always dependent on competition for the epitope.  For 
example 2D7 effectively blocks CCR5 use by R5 and R5X4 strains, yet in two studies, 
mutation of the CCR5 2D7 binding site had no impact on CCR5 use (Rabut et al., 1998; 
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Siciliano et al., 1999), indicating the 2D7 epitope itself is not required for infection by 
HIV-1.   It has been proposed that 2D7 inhibits HIV-1 infection by blocking access to 
critical residues in the transmembrane core of CCR5 (Siciliano et al., 1999).  The results 
presented in this chapter do appear to show a relationship between the proximity of an 
antibody epitope to the CCR5 core and the ability of that antibody to inhibit infection, 
although only a limited number of antibodies were used.  Thus, these findings suggest the 
interactions with the ECLs, or possibly other residues near this region, make a significant 
contribution to regulating the efficiency of CCR5 use. 
 It is interesting that sensitivity to CCR5 antagonists correlated with lymphocyte 
CCR5 use but not sensitivity to the fusion inhibitor T20.  CCR5 antagonists are allosteric 
inhibitors that are thought to prevent HIV-1 infection by binding within the pocket 
created by the extra cellular loops and altering the conformation of the coreceptor (Dragic 
et al., 2000).  T20 is a steric inhibitor that binds to HR1 in gp41 and prevents formation 
of the 6-helix bundle that is required for membrane fusion (Rimsky, Shugars, and 
Matthews, 1998; Wild, Greenwell, and Matthews, 1993).  Mutations in the coreceptor 
binding site that reduce Env binding invariably increase sensitivity to coreceptor 
antagonists, but the same mutations do not always have a similar effect on T20 sensitivity 
(Biscone et al., 2006; Reeves et al., 2002; Reeves et al., 2004).  From these relationships, 
it appears that efficiency of the Env-coreceptor interaction may not be inextricably linked 
to the efficiency of the subsequent conformational changes in gp41.  This also implies 
that sensitivity to coreceptor antagonists measures the efficiency of a single step in the 
fusion process.  In light of that possibility, my findings suggest that Envs with more 
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efficient interactions with CCR5 likely have a higher affinity for the coreceptor, although 
this would have to determined by measuring affinity for CCR5. 
 The findings in this study indicate that R5X4 strains vary in the efficiency of 
interaction with CCR5, and the variation in Env-CCR5 interaction efficiency impacts 
coreceptor use on primary lymphocytes.  Specifically, R5X4 HIV-1 with more efficient 
Env-CCR5 interactions infect CD4+ lymphocytes using CCR5 at much higher levels than 
viruses with inefficient interactions with the coreceptor.  I also discovered that this 
variation in Env-CCR5 interaction may be, at least in part, determined by interactions 
with ECLs or residues proximal to this region, based on sensitivity to ECL2 antibodies 
and coreceptor antagonists.   
 Notably, 89.6, the virus with the least efficient interactions with CCR5, is also the 
virus that failed to respond to increased CCR5 expression on CD4+ lymphocytes in 
chapter 1.  The barrier to CCR5 use by this strain and the factors in Env that regulate 
primary cell coreceptor usage and preference have not been identified, but this field 
necessitates further study if we are to fully understand pathogenesis by R5X4 HIV-1. 
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Chapter V - Molecular determinants within Env that regulate 
coreceptor use on CD4+ lymphocytes 
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Introduction 
The spectrum of lymphocyte CCR5 use by the R5X4 viruses studied here is 
dependent on the efficiency of the Env-coreceptor interaction, and variation in this 
interaction is Env-dependent.  Although many domains in Env influence interactions with 
coreceptor, the V3 domain is the primary determinant of coreceptor use, and it is thought 
to directly interact with the coreceptor (Choe et al., 1996; Cormier and Dragic, 2002; 
Cormier et al., 2000).   The V3 domain is also a critical determinant of viral phenotype.  
In CXCR4/CD4+ T cell lines, X4 and R5X4 viruses are able to induce syncytia (SI 
variants) while R5 strains are nonsyncytium inducing (NSI) in these cells (Björndal et al., 
1997).  This phenotypic difference between strains is based on coreceptor use and is 
largely determined by the V3 domain (Björndal et al., 1997; de Jong et al., 1992b).  
Comparative analysis of the V3 sequence of HIV-1 viruses with distinct phenotypes has 
led to the identification of features within this domain that are linked to use of CCR5 or 
CXCR4.  As outlined in chapter 1, a high net positive charge and the presence of 
positively charged amino acids at positions 11 and 24 or 25 (positions 306 and 319 or 320 
using HXB2 Env numbering) are well-known features associated with CXCR4 use by 
HIV-1 (Cardozo et al., 2007; Fouchier et al., 1992; Milich, Margolin, and Swanstrom, 
1993).  Several position specific scoring matrices (PSSM) have been developed to predict 
coreceptor use from V3 sequences based on large databases of viruses characterized as 
R5 vs X4 (X4/R5 PSSM) or NSI vs SI (SI/NSI PSSM) (Jensen et al., 2003).  The 
presence of these specific features within V3 and the related PSSM algorithm distinguish 
X4 from R5 viruses with reasonably high although imperfect accuracy; however, the V3 
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of R5X4 strains are more varied and do not always conform to this paradigm.  Presently, 
it is unclear how variability in V3 relates to coreceptor use by R5X4 viruses, particularly 
on primary CD4+ lymphocytes.   
The spectrum of lymphocyte CCR5 use by R5X4 strains includes variants with 
marginal use of this coreceptor, such as 89.6.  Unlike the other R5X4 viruses in this 
category, increased CCR5 expression on CD4+ lymphocytes did not enhance CCR5 use 
by 89.6, and severely impaired lymphocyte CCR5 use by this virus correlated with 
inefficient interactions with CCR5 by a number of different measures.  These findings 
together suggest restricted CCR5 use by 89.6 is dependent on the viral Env.  
Determinants within the 89.6 Env that impact coreceptor use have been identified in V3.  
Deletions on either side of the 89.6 Env V3 base abrogate CCR5 use, while deleting a 
section of stem that contains residue 306 abolished CXCR4 use by this virus (Nolan, 
Jordan, and Hoxie, 2008).  Another study attempted to derive variants of 89.6 resistant to 
CXCR4 inhibitors on cell lines expressing both coreceptors and identified a change from 
arginine to serine at position 306 that conferred resistance through enhanced CCR5 use 
(Maeda, Yusa, and Harada, 2008).   A recent study of other R5X4 viruses also suggests a 
role for amino acid 306 in modulating coreceptor use.  The efficiency of CCR5 and 
CXCR4 use on primary cells for brain versus blood or spleen-derived R5X4 envelopes 
was linked to the presence of a serine or arginine, respectively, at position 306 in V3 
(Gray et al., 2009).  Thus, residue 306 within Env appears to be a critical determinant of 
coreceptor use for 89.6 and for other R5X4 viruses, but it is not known whether the 
amino acid at this position contributes to restricted lymphocyte CCR5 use by 89.6 or the 
spectrum of lymphocyte CCR5 use by the other R5X4 viruses. 
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The goals of this chapter are to assess whether elements in V3 regulate 
lymphocyte CCR5 use by R5X4 viruses, and to identify determinants in the 89.6 Env that 
are responsible for the severely impaired lymphocyte CCR5 use by this virus.  To do this, 
the viral phenotype of each R5X4 virus was predicted using a V3-based position-specific 
scoring matrices (PSSM)-algorithm, and the relationship between predicted phenotype 
and lymphocyte CCR5 use by R5X4 viruses was evaluated.  Eventhough all strains tested 
were R5X4 in indicator cells, I found that those with greater lymphocyte CCR5 use were 
predicted to be NSI viruses, while viruses with poor lymphocyte CCR5 use were 
predicted to be SI viruses.  To determine the factors within the 89.6 Env that regulate 
lymphocyte CCR5 use, I mutated R306 in 89.6 to serine (89.6 R306S).  In addition, the 
role of this residue in regulating coreceptor use by other R5X4 viruses was assessed by 
mutating the same residue in C2-16, the R5X4 Env with greatest lymphocyte CCR5 use, 
from serine to arginine (C2-16 S306R).  I found that an arginine at this position was 
associated with increased sensitivity to CCR5 blocking agents for both 89.6 and C2-16.  
Moreover, viruses with an arginine at residue 306 were more dependent on the N-
terminus of CCR5 for infection.  My results also show the presence of a serine at position 
306 dramatically enhanced CCR5 mediated infection of CD4+ lymphocytes by 89.6, and 
switched coreceptor preference from CXCR4 to CCR5 on these cells.  However, arginine 
at this position had no impact on lymphocyte coreceptor use by C2-16.  Thus, the amino 
acid at position 306 regulates interactions with CCR5 for 89.6 and C2-16; it also 
regulates coreceptor use on primary lymphocytes by 89.6. 
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Results 
Relationship between V3 sequences and CD4+ lymphocyte coreceptor preference 
The V3 region is a major determinant of coreceptor use, and position-specific 
scoring matrix (PSSM) algorithms based on variations in this domain are frequently used 
to predict viral phenotype.  Two widely used algorithms are based on viruses phenotyped 
by syncytia induction in CXCR4/CD4+ cell lines (SI/NSI PSSM) or on coreceptor use in 
indicator cells (X4/R5 PSSM), which are highly related although not completely 
concordant features (Jensen et al., 2003).  However, such algorithms are typically less 
able to identify dual-tropic R5X4 than single coreceptor R5 and X4 variants.  More 
importantly, while used for indicator cell coreceptor use prediction, they have not been 
applied to selective use of coreceptors on primary cells.  Therefore, we applied the PSSM 
algorithms to V3 sequences from Envs in our panel to determine whether primary CD4+ 
T cell coreceptor usage among R5X4 HIV-1 might be associated with sequences in V3 
(Fig. 5.1a).  Strikingly, we found that prediction of an NSI phenotype based on V3 
sequence was associated with significantly more efficient use of lymphocyte CCR5 (Fig. 
5.1a & b).  Conversely, R5X4 viruses with more restricted entry through lymphocyte 
CCR5 were predicted to be SI.  Thus, while unable to identify these R5X4 strains as a 
group, the SI/NSI algorithm appears to discriminate among R5X4 strains and predict 
relative efficiency of lymphocyte CCR5 use based on V3 determinants.  In contrast, there 
was no link between primary lymphocyte coreceptor usage and predicted coreceptor 
phenotype based on V3 sequences using the X4/R5 coreceptor prediction algorithm.   
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Figure 5.1. R5X4 HIV-1 CCR5 use on CD4+ lymphocytes is associated with the predicted viral 
phenotype.  
V3 sequences from each virus were analyzed using the NSI/SI or X4/R5 PSSM algorithm.  The table shows 
an alignment of V3 sequence from R5X4 HIV-1.  Amino acids 11 (306) and 24/25 (319/320) are denoted in 
bold.  The coreceptor use on primary lymphocytes for each R5X4 virus is shown (from Fig. 3.2).  Predicted 
phenotypes are denoted by number with 1=SI or X4 and 0=NSI or R5 (A). Mean CCR5 use on CD4+ 
lymphocytes by R5X4 HIV-1 grouped by predicted viral phenotype.  R5X4 viruses were grouped by SI or 
NSI phenotype from (A) with CCR5 use for each virus represented by black circles.  The mean lymphocyte 
CCR5 use for each group was calculated, and the means were compared using a two-tailed, unpaired t-test 
in GraphPad Prism 4 software (***p<0.0001) (B). 
B. 
A. 
Strain  V3 sequence  CD4+ PBL 
%CCR5 use 
V3 Net 
Charge 
PSSM 
SI/ NSI 
PSSM 
X4/R5  
Ba l  CTRPNNNTRKSIHIGPGRALYTTGEIIGDIRQAHC 100  3  0
 
 0  
C2-16  ............TM....VY............... 5 2  3  0  0  
C2-22  ............TM....VY............... 3 9  3  0  0  
NR 1 0  ............A.....SF.A..R.......... 3 9  5  0  0  
NR 8  ............A.....SF.A..R.......... 3 5  5  0  0  
NR 1 1  ............A.....SF.A..R.......... 2 6  5  0  0  
DH1 2  ..........G.TL....VF......V....K... 1 2  4  1  0  
R3A ....G.....RVTL....VY....Q......K... 1 1  5  1  1  
DR 1  .I.........MTL...KVF....-VT....K... 1 5  5  1  0  
DR 1 7  .I.........MTL...KVF....-VT....K... 8  5  1  0  
DR 8  .I.........MTL...KVF....-VT....K... 4  5  1  0  
89.6  .........RRLS......F.ARRN.......... 4  7  1  1  
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Interestingly, most of these R5X4 Envs were predicted to be R5 by the X4/R5 PSSM 
matrix, which differed from the SI/NSI algorithm results.  Thus, while the V3-based 
PSSM is an incomplete predictor of coreceptor use for R5X4 strains, it does appear to 
predict the relative coreceptor preference on lymphocytes suggesting an important role of 
V3 in regulating coreceptor interactions. 
 A high net positive charge and positively charged amino acids at position 306 and 
319/320 of V3 are typically associated with CXCR4 use, whereas R5 strains typically 
lack these determinants.  R5X4 strains can use CXCR4, but these viruses often lack many 
of the features common in the V3 of X4 strains.  However, variability in V3, including 
the presence or absence of hallmarks of CXCR4 use, may be associated with coreceptor 
use on primary lymphocytes by R5X4 strains.  To assess this, the V3 net charge, as well 
as the identity of the amino acids at positions 306 and 319/320, were evaluated to 
determine if they were linked to CCR5 use on CD4+ T cells by the R5X4 viruses (Fig. 
5.1a).  This analysis revealed most of R5X4 strains in this panel have V3 charges that are 
only slightly higher than the R5 strain, Bal.  Positively charged amino acids were 
uncommon at residues 306 or 319/320, and there was no consistent connection between 
positive charges at these positions and lymphocyte CCR5 use by the R5X4 viruses.   
Interestingly, while the spectrum of CCR5 use could not be defined by the residues at 306 
and 319/320 or the V3 net charge, the viruses on both extremes of the CCR5-use 
spectrum did adhere to these rules.  C2-16 and C2-22, the viruses with the greatest CCR5 
use on lymphocytes, had net positive charges equal to Bal, and these viruses did not have 
basic residues at either V3 stem position.  Alternatively, 89.6, which had the poorest use  
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Figure 5.2.  The amino acid at position 306 in Env does not affect coreceptor use on U87 cells by 89.6 
or C2-16.   
The amino acids of envelope V3 regions of 89.6 and C2-16 are shown, along with the 89.6 R306S and C2-
16 S306R mutations, which correspond to position 11 of the V3 domain (A).  U87/CD4, U87/CD4/CCR5 
and U87/CD4/CXCR4 were infected with wild-type and mutant 89.6 and C2-16 luciferase pseudotype 
viruses. The results are presented as the RLUs measured from cell lysates 3 days after infection (B). 
 
 
 A.  
 89.6            C T RPN N NTR R RLSIG P GRA F YAR R NII G DIR Q AHC 35 
 89.6 R 306 S      • • ••• • ••• • S•••• • ••• • ••• • ••• • ••• • ••• 35 
 
 
 C2-16           C T RPN N NTR K SITMG P GRV Y YTT G EII G DIR Q AHC 35 
 C2-16 S30 4 R     • • ••• • ••• • R•••• • ••• • ••• • ••• • ••• • ••• 35 
 
B. 
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of lymphocyte CCR5, had a much higher V3 charge than any other R5X4 strain, and it 
was the only clone with basic amino acids at both positions 306 and 319 in this study.   
This result also suggests that elements within V3 contribute to regulation of coreceptor 
use by R5X4 viruses on lymphocytes. 
 
R306 is associated with increased sensitivity to inhibition by 2D7 and Maraviroc and less 
efficient interactions with CCR5 
While CCR5 use on CD4+ lymphocytes by R5X4 envelopes was bolstered by 
increasing CCR5 expression, this measure had little effect on lymphocyte CCR5 use by 
89.6.  Therefore, for this virus, we wished to address the Env side of the Env-CCR5 
interaction by determining if specific changes within V3 might alter the efficiency of 
CCR5 use and affect lymphocyte entry.  I speculated that the amino acid at position 306 
within Env might be involved in determining the efficiency of 89.6 Env-CCR5 
interaction, since several studies have shown that this residue can influence coreceptor 
use for 89.6 and other R5X4 strains (Gray et al., 2009; Maeda, Yusa, and Harada, 2008; 
Nolan, Jordan, and Hoxie, 2008).  To test this notion, R306 in 89.6 was mutated to serine 
(89.6 R306S; Fig. 5.2a).  In contrast to 89.6, the R5X4 Env with greatest lymphocyte 
CCR5 use, C2-16, has a serine at position 11 in V3.  Therefore, we also mutated the 
serine at this position in C2-16 to arginine in order to assess the converse effect (C2-16 
S306R) (Fig. 5.2a).  Both Envs remained R5X4 in U87/CD4/coreceptor cells (Fig. 5.2b).   
Sensitivity to CCR5 antagonists and mAbs are one method used to probe Env-coreceptor 
interactions, so I employed these inhibitors to determine whether mutations at residue 
306 within the 89.6 and C2-16 V3 domains had an effect on interactions with CCR5.    
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Figure 5.3. Residue R306 in Env is associated with less efficient interactions with CCR5.   
U87/CD4/CCR5 cells were not treated or pretreated with increasing concentrations of Maraviroc (A) or 
2D7 (B), then infected with wt and mutant 89.6 and C2-16 in the continued presence of blocker.  Results 
are presented as the luciferase activity in the presence of drug normalized to luciferase activity in the cell 
lysate of untreated cells.  Affinofile cells expressing a fixed level of CD4 and differing levels of CCR5 
were infected with wild-type and mutant 89.6 and C2-16 luciferase pseudotype viruses. The results are 
shown as the luciferase levels at each CCR5 density normalized to infection levels on cells expressing the 
maximum density of CCR5 (C). 
C. 
B. A. 
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Infection of U87 cells by wt and mutant 89.6 and C2-16 was inhibited at the highest 
Maraviroc concentrations (Fig. 5.3a).  As seen in earlier studies, wt 89.6 was 
substantially more sensitive to inhibition by Maraviroc than wt C2-16, which required 
approximately one log higher concentration of the drug to completely inhibit entry.  The 
R306S mutation in 89.6 resulted in a decrease in sensitivity to Maraviroc, while the 
S306R mutation in C2-16 increased sensitivity to this CCR5 antagonist (Fig. 5.3a).   
Infection of U87 cells in the presence of mAb 2D7 resulted in a similar inhibition pattern, 
with wt 89.6 and C2-16 being the most and least sensitive to inhibition by the mAb, 
respectively (Fig. 5.3b).  The 89.6 mutant R306S showed reduced sensitivity to 2D7 
compared to wt 89.6, and the reciprocal S306R mutation in C2-16 lead to increased 2D7 
sensitivity for this virus relative to wt C2-16.  These findings suggest that the residue at 
position 306 in Env modulates Env-CCR5 interactions.  In particular, the presence of 
arginine at residue 306 decreases the efficiency of the Env-CCR5 interaction while serine 
at this position enhances interaction.  
The changes in sensitivity to CCR5 blockers caused by mutations at position 306 
suggested that the identity of the amino acid at this position could also impact how 
efficiently viruses used CCR5 to infect target cells.  To address this question, we infected 
293 Affinofiles expressing a fixed level of CD4 and varying levels of CCR5 to test the 
effect of the Env mutations on the efficiency of CCR5 use in that system.  As noted in 
chapter 4, infection by 89.6 decreased markedly as CCR5 density on Affinofiles dropped 
from maximal to minimal levels.  Replacing the arginine at position 306 with serine 
resulted in a two-fold enhancement of entry at the lowest CCR5 levels, reaching a 
relative entry efficiency comparable to that for C2-16 (Fig. 5.3c).  In contrast, the C2-16 
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S306R mutation had some effect on entry efficiency at intermediate CCR5 levels, but not 
at the lowest CCR5 density; which most closely mimics those on primary CD4+ 
lymphocytes (Fig. 5.3c).  
 
Impaired CCR5 use on CD4+ lymphocytes by 89.6 is reversed by the R306S mutation 
within the V3 region 
Since residue 306 modulates the efficiency of CCR5 use, it might also regulate 
the ability or inability of 89.6 to use CCR5 on lymphocytes.  This question was addressed 
by evaluating coreceptor use on primary CD4+ T cells by wild type and mutant 89.6 and 
C2-16.  As shown in Fig. 5.4a, the R306S mutation dramatically enhanced use of 
lymphocyte CCR5 for 89.6.  In addition, the R306S change also decreased CXCR4 
mediated infection for the 89.6 mutant.  Importantly, this dramatic shift in lymphocyte 
coreceptor use occurred eventhough the mutant virus, like parental 89.6, remained R5X4 
in indicator cells (Fig. 5.2b), albeit with some increase in relative CCR5 use associated 
with the mutation.  In fact, 89.6 R306S showed a preference for CCR5 use on 
lymphocytes, in contrast to wild type 89.6, which was essentially restricted to CXCR4 for 
entry into these cells (Fig. 5.4b). Unlike 89.6, CCR5 use on CD4+ lymphocytes by strain 
C2-16 was not affected by the converse S306R mutation (Fig. 5.4a & b).   
Thus, replacing the positively charged arginine with serine at residue 306 in the 
89.6 Env increased the efficiency of CCR5 use, and resulted in preferential infection of 
CD4+ lymphocytes through CCR5, reversing its otherwise strict dependence on CXCR4  
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Figure 5.4. Residue 306 in Env regulates CCR5 use on CD4+ lymphocytes for 89.6 but not C2-16.   
PHA stimulated CD4+ lymphocytes were infected with wild-type and mutant 89.6 and C2-16 luciferase 
pseudotype viruses in the presence or absence of AMD3100, Maraviroc or a combination of both inhibitors.  
The results are representative of the average of three experiments on cells from different donors each 
performed in duplicate.  The results are presented as the RLUs measured from cell lysates 4 days after 
infection (A) or the RLUs for each treatment condition normalized to infection of untreated cells (B). 
A 
B 
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in those cells.  However, the amino acid at this position is not a critical determinant for 
all R5X4 viruses, since converting serine to arginine at that residue did not notably  
impact the efficiency of CCR5 use or coreceptor preference on primary lymphocytes by 
the C2-16 Env, indicating that other context-dependent factors are involved as well. 
 
Residue R306 increases Env dependence on the CCR5 amino terminus  
 Residue R306 is located in the stem of the V3 loop.  This region of the V3 loop is 
thought to interact with the CCR5 ECLs, and mutations or deletions at this site in other 
Envs has been associated with changes in interaction with this coreceptor (Cormier and 
Dragic, 2002; Gray et al., 2009; Nolan et al., 2009).  To determine how mutations at 
position 306 in Env impact interactions with CCR5, wt and mutant 89.6 and C2-16, along 
with the R5 virus JRFL, were used to infect 293 cells that expressed CD4 and wt CCR5 
or versions of this coreceptor containing deletions of the N-terminus.  All coreceptors 
were expressed at similar levels on the cell surface based on staining using the ECL2 
mAb 2D7 (data not shown). 
 As shown in figure 5.5, infection by wt 89.6 was substantially reduced on cells 
expressing CCR5 that lacked four N-terminal residues (∆2-5), and deletion of eight 
amino acids from this domain (∆2-9) completely abolished infection by this virus.  
Conversely, infection of cells expressing ∆2-5 by 89.6 R306S was two fold greater than 
infection by wt virus, and unlike wt 89.6, the mutant virus used ∆2-9 to infect 293 cells 
(Fig. 5.5a).  For C2-16, the ∆2-5 deletion had minimal effect on infection by wt or mutant 
virus, and neither virus efficiently used ∆2-13 for infection.  However, infection of cells  
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Figure 5.5. Envs with R306 are more dependent on the N-terminus of CCR5 for infection.   
293 cells expressing CD4 and mutant CCR5 with either N-terminal deletions (A) or N-terminal Y to A 
substitutions (B).  Following transfection, cells were infected with 5ng of wt and mutant 89.6 and C2-16 
luciferase pseudotypes.  Results are shown as the luciferase activity in cell lysates from cells expressing 
mutant coreceptor normalized to infection of 293 cell expressing wt CCR5 after 3 days in culture.  Results 
are representative of two infections each performed in triplicate. 
A. 
∆2-5 ∆2-9 ∆2-13 
B. 
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expressing ∆2-9 by wt and mutant C2-16 revealed stark differences in how these viruses 
are affected by changes in the CCR5 N-terminus.  While infection of cells expressing ∆2-
9 by wt C2-16 was only 10% lower than infection using wt CCR5, the S306R conversion 
resulted in a virus incapable of using this mutant coreceptor (Fig. 5.5a). Unlike the R5X4 
viruses, JRFL was able to use all three truncated coreceptors for infection (Fig. 5.5a).  
Thus, the identity of the residue at position 306 in Env is associated with different 
requirements for the CCR5 N-terminus.  Viruses with arginine at this position are more 
dependent on the N-terminus of CCR5 for infection, and serine at this position is 
associated with the ability to use CCR5 despite truncation of this domain. 
 There are four tyrosines in the N-terminus of CCR5, and these tyrosines can be 
sulfated (Farzan et al., 1999).  Tyrosine sulfation at residues 10, 14 and 15 in the CCR5 
N-terminus are thought to be critical for gp120 binding and HIV-1 infection (Cormier et 
al., 2000; Farzan et al., 1998; Farzan et al., 1999; Rabut et al., 1998).  Since the residue at 
position 306 regulates dependence on the N-terminus of CCR5, I thought it might also 
regulate dependence on the tyrosines in this domain.  Therefore, I sought to determine 
whether altering the tyrosines in the CCR5 N-terminus had a larger impact on infection 
by wt or mutant Env clones of 89.6 and C2-16, and if an arginine or a serine at position 
306 was associated with increased sensitivity to tyrosine mutation.  This was done by 
infecting 293 cells that expressed CD4 and wt CCR5 or CCR5 mutants in which an 
individual tyrosine is mutated to alanine.  All coreceptors were expressed at similar levels 
on the cell surface based on staining using the ECL2 mAb 2D7 (data not shown). 
 As shown in Fig 5.5b, infection by 89.6 on cells expressing the Y3A coreceptor 
was less than half that mediated by wild-type CCR5, and infection of cells expressing the 
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three other mutant coreceptors only approached 10% of wt levels (Fig. 5.5b).  In contrast, 
the 89.6 mutant carrying the R306S change was less affected by tyrosine mutation, 
consistently reaching infection levels on each mutant at least 20% higher than infection 
by wt virus, and use of the Y10A coreceptor was five fold greater for 89.6 R306S 
compared to 89.6 (Fig. 5.5b).  In contrast to 89.6, C2-16 was only modestly affected by 
the individual tyrosine mutations, whereas changing serine to arginine (C2-16 S306R) 
resulted in a virus with markedly reduced use of the Y14A and Y15A coreceptors, and 
that was also less able to use the Y10A coreceptor.  Interestingly, CCR5-mediated 
infection by JRFL was only slightly affected by any of these individual tyrosine 
mutations, which was similar to C2-16 and markedly different from 89.6 (Fig. 5.5).  
Thus, the presence of arginine at position 306 is associated with increased dependence on 
tyrosine residues in the N-terminus of CCR5, while serine at this position results in less 
dependence on these residues. 
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Conclusions 
 CCR5 use on CD4+ lymphocytes varies among the R5X4 strains, but it is 
generally low, and includes one virus, 89.6, that is almost completely unable to use 
lymphocyte CCR5 even after CCR5 expression is increased on these cells.  The V3 
domain in Env is a principal determinant of coreceptor use and interacts directly with the 
coreceptor.  In this chapter, I sought to determine the contribution of V3 to the spectrum 
of CCR5 use by R5X4 strains.   
 Using a PSSM algorithm, I found that viruses with greater lymphocyte CCR5 use 
were predicted to have an NSI phenotype while viruses that used this coreceptor poorly 
were classified as SI viruses.  Comparative analysis of V3 revealed that viruses at the 
extremes of the lymphocyte CCR5 use spectrum, C2-16 and 89.6, could clearly be 
distinguished by the absence or presence, respectively, of common hallmarks of CXCR4 
use, including the charge of the residue at position 306 in Env.  I mutated the amino acid 
at this position in 89.6 (R306S) and C2-16 (S306R) to determine its role in controlling 
CCR5 use by these viruses.  My findings show that the R306S change in 89.6 
dramatically enhanced lymphocyte CCR5 use and changed coreceptor preference on 
these cells from CXCR4 to CCR5.  However, the reciprocal mutation had no affect on 
lymphocyte coreceptor use by C2-16.  The presence of an arginine at position 306 was 
associated with increased sensitivity to CCR5-specific blockers and less efficient 
infection of Affinofile cells when compared to viruses with serine at this same position.  
Having an arginine instead of a serine at residue 306 was also associated with greater 
dependence on the CCR5 N-terminus for infection.  These results indicate that elements 
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within V3 determine the spectrum of lymphocyte CCR5 use by R5X4 strains, the amino 
acid at position 306 in Env regulates the efficiency of CCR5 use for 89.6 and C2-16, and 
R306 is responsible for the impaired use of lymphocyte CCR5 by 89.6. 
 The bridging sheet and base of V3 are thought to interact with the N-terminus of 
CCR5, while the tip and stem interact with the ECLs (Cormier and Dragic, 2002; 
Cormier et al., 2001; Huang et al., 2007).  The data presented here imply that the greater 
dependence on the CCR5 N-terminus displayed by R306 compared to S306 Envs results 
from reduced interactions between V3 containing R306 and the CCR5 ECLs.   Amino 
acids 306 and 319/320 in V3 are thought to create a surface in Env that is positively 
charged for X4 viruses or negatively charged for R5 strains (Cardozo et al., 2007).  While 
the charges of the residues at these positions for R5X4 strains do not always conform to 
this rule, 89.6 has positive charges at both positions, and C2-16 has a neutral residue at 
position 306 and a negatively charged residue at positions 320.  Differences in the charge 
of the surface created by amino acids 306 and 319/320 between 89.6 and C2-16 regulate 
interactions with residues in the ECLs of CCR5, and the strength of this interaction 
contributes to regulation of CCR5 use. 
Residue 306 in Env regulated CCR5 use by both 89.6 and C2-16, with serine at 
this position associated with more efficient Env-CCR5 interactions.   Most of the R5X4 
strains, including those with poor lymphocyte CCR5 use, had a neutral or acidic amino 
acid at this position, suggesting other residues may be responsible for the pattern of 
CCR5 use by these strains.  Positions 306 and 319/320 likely associate in space, and 
perhaps the amino acid at either of the later positions could contribute to regulation of 
lymphocyte CCR5 use by some of these strains.  The majority of the variability between 
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the V3 sequences of these R5X4 Envs is on either side of the tip, in residues that contact 
the ECLs.  For some viruses, basic amino acids are found at these residues, and perhaps 
these amino acids negatively contribute to Env-CCR5 interactions.  However, some of 
the R5X4 viruses with poor lymphocyte CCR5 use had no positive charges at either of 
these positions, and for these Envs, other domains may play an important role.  For 
instance, the V1-V2 region of DH12 can confer CXCR4 use to an R5 virus, and N-
glycosylation in this domain in the DH12 Env also influences the efficiency of CCR5 or 
CXCR4 use (Cho et al., 1998; Ogert et al., 2001).  Thus, while I show that regulation of 
lymphocyte CCR5 use by the R5X4 strain 89.6 is influenced by interactions between the 
ECLs and the residue at position 306, additional factors exist likely, both within and 
outside V3, that regulate this interaction. 
 The R306S change in the 89.6 Env was also associated with a decrease in the 
contribution of CXCR4 to infection of CD4+ lymphocytes.  V3 loops of X4 viruses have 
higher net positive charges than R5 viruses, and it has been proposed that this higher 
charge allows X4 viruses to utilize the negatively charged surface of CXCR4 (Chabot et 
al., 1999).  Deletion of residues 304-307 in the R3A and 89.6 Env abrogates CXCR4 use 
by these viruses, suggesting this region is critical for interactions with the CXCR4 ECLs 
(Nolan et al., 2009).  Thus, it is plausible that the amino acid at position 306 also 
contributes to regulation of CXCR4 use for some R5X4 viruses and that S306 is 
associated with reduced interactions with the CXCR4 ECLs.   
 It is interesting that changing the amino acid at position 306 had an impact on 
every measure of how efficiently 89.6 and C2-16 mutants used CCR5, but the S306R 
mutation did not alter CCR5 use on primary lymphocytes by C2-16.  The V3 loop of C2-
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16 has features that are very similar to R5 viruses, including a low net positive charge 
(+3) and the lack of positively charged amino acids at the two key residues in the V3 
stem.  The S306R mutation introduces a positive charge into Env, which should decrease 
interactions with the CCR5 ECLs.  It is possible that other residues within C2-16 Env 
continue to contact critical determinants in the ECLs, and, as a result, CCR5 use by the 
C2-16 mutant might be less affected.  An alternative possibility is that the density of 
CCR5 expressed on lymphocytes is above the threshold required by both wt and mutant 
C2-16, and this would make it is difficult to observe a difference in lymphocyte CCR5 
use by the two strains.  Presently, it is unclear what accounts for the robust use of 
lymphocyte CCR5 by the C2-16 mutant. 
PSSM predictive algorithms are not highly accurate for distinguishing R5X4 from 
single coreceptor-tropic viruses, but we found that among R5X4 variants, the SI/NSI 
matrix showed a strong correlation between “NSI-like” characteristics and greater 
lymphocyte CCR5 use, and “SI-like” and poorer lymphocyte CCR5 use.  These results 
further support the role of V3 in determining coreceptor preference in the context of 
primary cells and, in addition, further emphasize the limitations of indicator cells in 
predicting primary cell coreceptor use.  In contrast, the X4/R5 predictive matrix, based on 
coreceptor use in indicator cell lines, did not distinguish between R5X4 strains with 
greater or lesser lymphocyte CCR5 use.  Future studies will be needed to characterize the 
strains for which phenotype predictions differ between the scoring matrices, and 
determine whether these Envs may exhibit other distinguishing features in their 
interactions with primary cells.  
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 The role of particular Env domains in determining CCR5 or CXCR4 use has been 
well studied, however, the exact mechanisms underlying the discrimination of CCR5 and 
CXCR4 are still obscure.  Small changes in the viral Env can impact interactions with 
different domains of the coreceptor, and this can affect viral entry.  However, it is 
currently not known whether the structural determinants of CCR5 are equally exposed on 
different primary cell types or cells from different donors.  These questions have 
important implications for the design of coreceptor antagonists and the study of drug 
resistance.  Thus, understanding how changes in the HIV-1 Env alters interactions with 
the CCR5 structure and impacts primary cell coreceptor use is an extremely important 
topic. 
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Chapter VI - Discussion 
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 R5X4 strains are usually the first CXCR4-using viruses to emerge, and these 
variants appear late in disease with varying frequency in people infected with HIV-1 
from many of the group M subtypes (van Rij et al., 2000; Zhang et al., 1997; Zhang et al., 
1998).  During the acute and early phases of disease, R5 strains predominate (Liu et al., 
1996; Samson et al., 1996).  However, R5X4 strains also use CCR5 but fail to establish 
infections in recipients.  Selection against CXCR4 using variants may be the reason 
R5X4 viruses rarely seed new HIV-1 infections.  Alternatively, R5X4 strains may fail to 
transmit because CCR5 use by these variants is distinct from coreceptor use by R5 
strains.  The study of coreceptor use by R5X4 viruses may provide key insights into this 
important aspect of HIV-1 infection.    
Coreceptor use by HIV-1 strains is typically determined on cell lines that have 
been engineered to express CD4 and a coreceptor, and infection of these cell lines 
indicates which coreceptors a virus can use.  However, viruses may fail to infect primary 
cells using a coreceptor that it uses in indicator cell lines, raising questions of whether 
coreceptor use on cell lines accurately models coreceptor use on primary cells (Tokunaga 
et al., 2001).  The primary cell targets of HIV-1 express CCR5 and CXCR4, and a 
previous study from our lab demonstrated that prototype R5X4 viruses use CCR5 and 
CXCR4 to infect macrophages.  However, infection of CD4+ lymphocytes occurred 
predominately through CXCR4, whereas CCR5 was used poorly, if at all (Yi, Shaheen, 
and Collman, 2005).  For this dissertation, I utilized a variety of dual-tropic isolates 
representing a broad spectrum of phenotypes, to assess whether R5X4 strains vary in the 
ability to use CCR5 on lymphocytes, and what factors determined the use of this 
pathway.   
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Limited lymphocyte CCR5 use: implications for the evolution and transmission of 
R5X4 HIV-1 
Results presented in this dissertation indicate limited CCR5-mediated infection of 
CD4+ T cells by the R5X4 strains tested, which did not substantially contribute to overall 
infection levels when CXCR4 was available.  However, blocking CXCR4 use revealed a 
spectrum of lymphocyte CCR5 use among the R5X4 viruses.  CCR5 is expressed on a 
small percentage of CD4+ T cells, and increasing CCR5 expression noticeably improved 
CCR5 use for all R5X4 strains, except 89.6.  If CCR5 use was determined strictly by the 
percentage of cells expressing this coreceptor, then infection by R5X4 strains should be 
equivalent to that of R5 viruses.  CCR5 density varies within the population of CD4+ 
lymphocytes, and the variability in lymphocyte CCR5 use by R5X4 strains suggested that 
coreceptor density could be a factor in regulating lymphocyte CCR5 use.  However, other 
additional factors likely exist, since CCR5-mediated infection of CD4+ lymphocyte by 
89.6 was not enhanced by increasing CCR5 expression.  R5X4 and R5 strains with the 
greatest CCR5 use were proficient at detecting this coreceptor than antibody specific for 
CCR5, suggesting Env might also regulate use of this coreceptor on CD4+ lymphocytes. 
The R5X4 strains in this report exhibited a spectrum in their efficiency of 
lymphocyte CCR5 use, but none preferentially infected CD4+ T cells using this 
coreceptor.  On one hand, this is not surprising given the difference in number of cells 
positive for each coreceptor.  On the other hand, R5X4 strains emerge in vivo from R5 
strains in memory lymphocytes that express CCR5 and CXCR4, while later in infection, 
R5X4 along with X4 viruses are found mostly in the CCR5-/CXCR4+ naïve subset (van 
Rij et al., 2000).  Thus, it seems likely that some R5X4 strains would use CCR5 as the 
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predominant coreceptor to infect CD4+ T cells.  The fact that the R306S mutation in 89.6 
changes coreceptor preference on lymphocytes from CXCR4 to CCR5 indicates that this 
type of R5X4 Env can exist and that only minor changes may be required to shift 
between these two phenotypes.  Perhaps R5X4 viruses that predominately use CCR5 to 
infect lymphocytes emerge but then rapidly disappear from the viral quasispecies.  
Alternatively, evolution of R5X4 strains might never transit through a phase in which 
CCR5 use is dominant.  In a study of in vitro-derived R5X4 switch variants, the earliest 
CXCR4-using Envs were more sensitive to CCR5 antagonists and less efficient at using 
CCR5 for entry when compared to the parental R5 virus (Pastore, Ramos, and Mosier, 
2004), and the mutations conferring CXCR4 use were detrimental except when 
introduced with compensatory changes elsewhere in the envelope (Pastore et al., 2006).  
In vivo, R5 strains showed reduced ability to infect CCR5-low cells prior to the 
emergence of R5X4 viruses (Coetzer et al., 2008).  Thus, CXCR4 use may only emerge 
after compensatory mutations occur that have the effect of decreasing CCR5 use, 
suggesting that R5X4 evolution may not involve a phase of predominate lymphocyte 
CCR5 use.   
R5 viruses are responsible for establishing the majority of new HIV-1 infections, 
but it is still not clear why.  R5 strains are typically more macrophage-tropic than X4 
variants, and CCR5-dependent macrophage tropism was classically proposed as a 
possible reason (Liu et al., 1996; van't Wout et al., 1994; Zhu et al., 1993).  However, 
R5X4 strains also use CCR5 to infect primary macrophages, yet this strain is rarely 
transmitted (Liu et al., 1996; van't Wout et al., 1994; Yi, Shaheen, and Collman, 2005).  
Furthermore, recent studies using transmission pair isolates obtained near the time of 
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transmission enabling donor/recipient comparison, or PCR amplification and 
phylogenetic reconstruction of the successfully transmitted virus, reveal that these 
founder viruses are restricted to CCR5 and readily infect lymphocytes but typically infect 
macrophages inefficiently and/or no better than the donor variants (Isaacman-Beck et al., 
2009; Keele et al., 2008b; Salazar-Gonzalez et al., 2009).  The fact that R5X4 variants 
generally use lymphocyte CCR5 poorly relative to R5 viruses raises the possibility that 
these strains do not establish infections in recipients because use of CCR5 on 
lymphocytes is the critical determinant of transmission.  Alternatively, it remains possible 
that neither R5X4 nor X4 strains efficiently transmit because CXCR4 use is selected 
against during transmission or establishment of new infections in recipients (Cornelissen 
et al., 1995). 
 
Efficiency of CCR5 use by R5X4 HIV-1: implications for pathogenesis  
The variability in lymphocyte CCR5 use among the R5X4 strains, coupled with 
the observations that Envs at the extremes of this spectrum appeared to use CCR5 with 
different efficiencies, suggested that Env-coreceptor interactions influenced lymphocyte 
CCR5 use by R5X4 strains.  Experiments with CCR5-specific mAbs showed a significant 
correlation between greater lymphocyte CCR5 use and reduced sensitivity to ECL-2, but 
not N-terminal or multi-domain mAbs.  When sensitivity to entry inhibitors was assessed, 
reduced sensitivity to CCR5 small molecule antagonists, but not fusion inhibitor T20, 
also correlated with greater lymphocyte CCR5 use.  The link between coreceptor use and 
the efficiency of the Env-CCR5 interaction was further evaluated using cell lines with 
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regulated levels of CD4 and CCR5.  At physiologically relevant CD4 levels, R5X4 
strains with greater lymphocyte CCR5 use were less sensitive to reductions in CCR5 
density.  Moreover, there was a significant correlation between the ability to exploit low 
levels of CCR5 on this cell line and higher levels of lymphocyte CCR5 use.  These 
results suggest that variation in the efficiency of Env interactions with the ECLs of CCR5 
has an effect on efficiency of coreceptor use and contributes to the spectrum of 
lymphocyte CCR5 use by R5X4 strains.  These findings underscore the importance of the 
ECLs, in particular ECL2, in infection by R5X4 viruses, and raise the possibility that 
determinants in Env ultimately regulate lymphocyte CCR5 use by these viruses. 
The limited CCR5-mediated infection of lymphocytes by R5X4 HIV-1 raises 
questions of whether the efficiency of CCR5 use by R5X4 viruses has any impact on 
viral pathogenesis.  Although rare, R5X4 strains have been transmitted and were able to 
establish infection in recipients (Meissner et al., 2004; Yu et al., 1998).  Given the 
importance of CCR5 use in transmission, these viruses might be expected to utilize 
lymphocyte CCR5 more efficiently than R5X4 viruses that arise later.  Strain R3A was 
obtained from an unusual R5X4 acute infection (Meissner et al., 2004), but R3A was not 
among the R5X4 Envs with more efficient lymphocyte CCR5 use.  Paradoxically, the 
two variants with greatest relative efficiency in lymphocyte CCR5 use were NR10, from 
a late stage patient, and C2-16, from a CCR5-null subject; neither are clinical scenarios in 
which one might expect more efficient lymphocyte CCR5 use from the isolated virus.  
Macrophage infection is thought to be the major source of virus in tissue, a critical 
component of neuropathogenesis, and responsible for sustaining virus replication at very 
late stages of disease (Igarashi et al., 2001; Koenig et al., 1986; Schuitemaker et al., 
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1992).  Prototype and some primary R5X4 strains readily infect macrophages using 
CCR5, which may be explained by the higher density of CCR5 expressed on these cells 
compared with primary CD4+ lymphocytes (Lee et al., 1999b; Yi, Shaheen, and 
Collman, 2005).  However, use of this coreceptor may be dispensable since CXCR4 also 
serves as a viable coreceptor for R5X4 entry into these cells (Yi, Shaheen, and Collman, 
2005).  Thus, it remains to be determined how the efficiency of lymphocyte CCR5 use 
among R5X4 variants is linked to specific aspects of pathogenesis.  In addition, while X4 
use is common in subtype B HIV-1, it is less frequent among subtype C strains and, 
furthermore, the factors that regulate coreceptor interactions may differ for different 
subtypes (Lynch et al., 2009).  Further studies will be needed to determine the extent to 
which these findings apply to other subtypes 
 
V3 determinants that regulate CCR5 use by R5X4 HIV-1: implications for structural 
interactions with coreceptor 
The repeated correlation between measures of Env-CCR5 interaction efficiency 
and CCR5 use on lymphocytes suggested that elements within Env regulate lymphocyte 
CCR5 use.  Since V3 is the principal determinant of coreceptor use, I focused on how 
variation in this domain might regulate lymphocyte CCR5 use by R5X4 strains.  I 
discovered a relationship between the viral phenotype predicted using a V3-based PSSM 
algorithm and lymphocyte CCR5 use, with viruses that used this coreceptor well 
predicted to be NSI viruses and those that use it poorly identified as SI variants.   
Subsequent analysis of V3 sequences revealed that the two variants at the extremes of the 
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spectrum of CCR5 use, 89.6 and C2-16, differed in the presence of hallmarks associated 
with CXCR4 use, including the presence or absence, respectively, of a basic amino acid 
at position 306 in V3.  Evaluation of mutant compared to wt viruses showed that 89.6 
R306S was less sensitive to blocking CCR5 and was less dependent on the CCR5 N-
terminus for infection.  Conversely, the C2-16 S306R mutant was more sensitive to 
agents directed at CCR5 and was more dependent on the N-terminus of the coreceptor.  
The impact of these mutations on coreceptor use was determined by infecting primary 
lymphocytes, and the results indicated that the R306S mutation in 89.6 changed its 
coreceptor preference from CXCR4 to CCR5, while the reciprocal S306R change in C2-
16 did not alter coreceptor use.  These studies revealed that features within V3 likely 
determine the spectrum of lymphocyte CCR5 use, that the residue at position 306 in Env 
modulates the efficiency of CCR5 use for 89.6 and C2-16, and that R306 is responsible 
for impaired lymphocyte CCR5 use by 89.6.  
The V3 domain is a primary determinant of coreceptor use, however, the effect of 
subdomains within this region on primary cell coreceptor use has not been previously 
addressed.  Here, I show that a serine at position 306 is associated with greater 
lymphocyte CCR5 use by 89.6.  This occurs because serine at this residue enhances the 
efficiency of CCR5 use, likely through enhanced interactions with the CCR5 ECLs.  
Most of the R5X4 strains have serine at this position, but not all use CCR5 efficiently.  
PSSM results indicate that elements within V3 likely regulate lymphocyte CCR5 use by 
R5X4 viruses.  The majority of the variation in the V3 region is in stem and tip residues 
other than 306.  Thus, these stem and tip residues may regulate lymphocyte CCR5 use for 
the other R5X4 strains.  This would presumably occur through interactions with the 
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ECLs, since the V3 stem and tip are thought to interact with this domain of the 
coreceptor.  Interestingly, the C2-16 S306R mutation had an impact on the efficiency of 
CCR5 use by C2-16, but did not alter its coreceptor use on primary lymphocytes.  The 
reasons for this are unclear, but may involve other regions of Env or of V3.  Additionally, 
mutations at this position also affected CXCR4 use by 89.6, suggesting that residue 306 
may regulate interactions with CXCR4 for some viruses. 
 The ability to use CCR5 and CXCR4 must hinge on the ability of R5X4 strains to 
recognize conserved regions of each coreceptor, but it is unclear exactly how this is 
regulated.  Numerous studies indicate that the underlying architecture of CCR5 and 
CXCR4 are similar.  R5, X4 and R5X4 viruses are capable of using CCR5/CXCR4 
chimeras for infection, even when multiple discontinuous domains are exchanged 
(Karlsson et al., 2004; Pontow and Ratner, 2001).  Removal of an N-linked glycosylation 
site in the N-terminus or a substitution that removes a negatively charged residue in ECL-
2 of CXCR4 permits use of this coreceptor by R5 viruses (Chabot and Broder, 2000; 
Chabot et al., 2000; Chabot et al., 1999).  As mentioned, deletion of amino acids 
surrounding the V3 loop of R3A and 89.6 abrogated CXCR4 use; the resulting virus 
retained CCR5 use but was resistant to CCR5 antagonists (Nolan, Jordan, and Hoxie, 
2008).  These findings indicate this segment of the V3 stem interacts with the ECLs of 
CCR5 and CXCR4.  Residue 306 is located in this region of V3 and it modulates Env-
CCR5 and potentially Env-CXCR4 interactions for some viruses.  Perhaps position 306 
serves as a pivot point in Env, and the identity of the amino acid at this position allows 
the virus to favor one coreceptor over another by recognizing a critical ECL determinant 
that is similar in both coreceptors but distinct enough to allow the virus to distinguish 
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CCR5 from CXCR4.  For other R5X4 strains, in which amino acid 306 may not regulate 
the efficiency of CCR5 use, another stem or tip residue in V3 may play this role.  
Summary and final conclusions 
In summary, using a panel of primary and prototype R5X4 HIV-1 variants, this 
study confirms that these strains are highly skewed towards CXCR4 use for entry into 
CD4+ T cells.  However, among the isolates tested, there is a range in the relative ability 
to use CCR5 on primary lymphocytes, although we did not identify an evident 
relationship between relative lymphocyte coreceptor use and the clinical context in which 
the R5X4 Envs were derived.  The ability to use lymphocyte CCR5 by R5X4 variants 
was linked to greater efficiency in CCR5 interactions based on antibody and small 
molecule antagonist blocking studies, and this was dependent on residues within V3.  
Furthermore, the barrier to CCR5 use could be overcome by CCR5 over-expression in 
lymphocytes for most of the R5X4 isolates or, by mutating Env to enhance coreceptor 
interaction efficiency.   
These finding lead to the conclusion that potential CCR5-mediated infection of 
CD4+ lymphocytes is limited by the proportion of cells that express CCR5, but actual 
CCR5 use by a specific R5X4 virus is regulated by the threshold of CCR5 it requires for 
infection.  The differences in CCR5-Env interactions identified among the R5X4 strains 
here, which are dependent on determinants within the Env V3 that interact with the 
CCR5 ECLs, regulate the threshold of CCR5 required for entry. Thus, the efficiency of 
the Env-CCR5 interaction is the principal factor underlying differences in CCR5-
mediated target cell availability and, ultimately, lymphocyte CCR5 use for each isolate.    
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Better understanding of the viral and cellular factors that control coreceptor use by HIV-1 
strains is critical to understanding the impact of viral evolution on target cell tropism.   
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